

## **Diplomate Case 4: Angle closure spectrum disease**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16

### **ABSTRACT**

Although open-angle glaucoma is generally more common than the angle-closure form, patients with angle-closure glaucoma tend to have worse visual prognosis and higher rates of blindness. Patients with acute angle closure tend to have better visual outcomes in comparison to patients with intermittent or chronic closure, due to an increased likelihood to present to the eye care practitioner early enough with the onset of symptoms. Case detection of patients with angle closure is critical for preventing vision loss, as early intervention strategies tend to have reasonably good outcomes. The current gold standard of anterior chamber angle assessment is gonioscopy, even in the face of non-invasive technologies that allow rapid imaging of the angle. As a result, grading systems of angle closure focus almost exclusively on the gonioscopic findings, which makes this a critical skill in the glaucoma patient. This report describes a case of a patient with primary angle closure, and highlights the importance of gonioscopy in clinical assessment of the glaucoma suspect.

17 **INTRODUCTION**

18 Glaucoma is one of the leading causes of irreversible blindness, and its prevalence is expected to  
19 increase over time due to the ageing and longevous population in most parts of the world.<sup>1, 2</sup>  
20 Although open-angle glaucoma is generally more common in most parts of the world, patients with  
21 angle-closure glaucoma tend to have worse visual prognosis and higher rates of blindness.<sup>3-5</sup> In  
22 angle-closure, obstructed aqueous outflow can cause significant increases in intraocular pressure  
23 that then leads to glaucomatous nerve damage and field loss. Acute angle closure, which is the form  
24 of the disease that is classically described in medicine with its “hot” eye and significant visual and  
25 systemic symptoms (e.g. Lowe et al.<sup>6</sup>), involves a hard and fast increase in intraocular pressure with  
26 accompanying anterior ocular signs (corneal oedema, bulbar injection) and leads to glaucomatous  
27 nerve damage through a necrotic process, contrasting with the usual slow, apoptotic process  
28 occurring in open angle glaucoma.<sup>7</sup> Patients with acute angle closure, interestingly, tend not to have  
29 vision loss commensurate with the severity of presentation precisely because these patients  
30 commonly present promptly to the eye care practitioner to receive ophthalmic care.<sup>8</sup> Indeed, in  
31 some studies in high-risk groups, most patients may not be symptomatic at all (approximately 65-  
32 86%),<sup>9-11</sup> nor does the symptom necessarily predict final visual outcome.<sup>12</sup>

33 Case detection of non-acute or symptomatic forms of angle closure disease appears to be  
34 opportunistic, and in fact relies significantly on practitioner skill with the gonioscopes to accurately  
35 assess the anterior chamber angle. The sinister nature of intermittent or chronic angle closure,  
36 creeping up from narrow angles, bears some similarity with open-angle glaucoma in the quiet  
37 nature of the disease process. In such cases, early detection and intervention is paramount to patient  
38 case detection, though sadly overall patients with glaucoma still present with significant vision loss  
39 at the point of diagnosis.<sup>13</sup> Furthermore, it is not uncommon to find cases of undetected angle  
40 closure disease in a significant proportion of patients in the ophthalmic population, including those  
41 who have previously received a diagnosis of open angle glaucoma.<sup>14</sup>

*Diplomate case 4: Primary angle closure*

42 The present case illustrates a patient presenting with angle closure spectrum disease. The  
43 appropriateness of the management was contingent upon accurate diagnosis, which was  
44 supplemented using advanced imaging modalities. Various techniques used in the assessment of the  
45 anterior chamber angle are extensively discussed.

46

47 **CASE REPORT**

48 A 65 year-old European female was referred for an opinion regarding the anterior chamber angle.  
49 She had no presenting ocular symptoms of note, such as blurry vision, redness, soreness, floaters,  
50 flashes or haloes around lights. She did not report symptoms of nausea or vomiting. She had no  
51 history of prior ocular injuries, surgeries, laser or disease of note. She did not have a family history  
52 of glaucoma or blindness. Her medical history was unremarkable, with no diabetes, hypertension,  
53 hypotension, thyroid disease, sleep apnoea or migraine.

54 Best corrected acuities were 20/20 OD and OS with manifest refraction of +2.75/-0.75x90 OD and  
55 +2.50/-0.75x90 OS. Pupil testing was unremarkable with no relative afferent pupillary defect.

56 Extraocular motilities were full.

57 Intraocular pressures (Goldmann applanation tonometry) at 10:01 am were 11 mmHg OD and 13  
58 mmHg, in the context of central corneal thicknesses of 555 microns OD and 550 microns OS found  
59 using Scheimpflug imaging (Pentacam HR; Oculus). Both were within the normative range. Her  
60 axial length was 22.70 mm OD and 22.78 mm OS found using the IOL Master (Carl Zeiss  
61 Meditec, Dublin, CA).

62 Slit lamp biomicroscopy of the anterior segment showed very narrow van Herick angle estimation  
63 (<0.1:1 temporally OU). There was a dense corneal arcus in both eyes. The conjunctiva was clear  
64 and quiet in both eyes. There were early age-related cataracts (grade 1) in both eyes. The iris

*Diplomate case 4: Primary angle closure*

65 appeared flat with no evidence of transillumination defects. The anterior chamber was otherwise  
66 quiet.

67 Stereoscopic fundus examination showed a small-sized disc with shallow cup in both eyes (Figure  
68 1). The neuroretinal rim and adjacent retinal nerve fibre layer reflectivity appeared intact in both  
69 eyes, with no evidence of a disc haemorrhage. The macula was also clear. There were some drusen  
70 temporal and supero-temporal to the fovea OD and OS, respectively. Optical coherence tomography  
71 results of the optic nerve head, retinal nerve fibre layer and ganglion cell-inner plexiform layer  
72 thickness were all within the normative range and showed no evidence of glaucomatous damage  
73 (Figures 2 and 3).

74 Gonioscopy was performed using a G4 lens (Volk Optical Inc., Mentor, OH) following instillation  
75 of topical anaesthetic (oxybupracaine) and the application of a viscous coupling fluid. The  
76 gonioscopic results were: pigmented trabecular meshwork inferiorly, anterior trabecular meshwork  
77 nasally and Schwalbe's line or no structures superiorly and temporally OD and OS. The iris contour  
78 was steep in most areas. Where the pigmented trabecular meshwork could be seen, the level of  
79 pigmentation was moderate. Indentation gonioscopy was subsequently performed and revealed  
80 deeper angle structures (scleral spur and ciliary body band) in the quadrants of narrowing.

81 Goniophotographs were taken for this patient in primary case under dim illumination (Figures 4-7).

82 Further imaging of the anterior segment was conducted. Scheimpflug imaging showed anterior  
83 chamber depth of 2.10 mm OD and 2.13 mm OS, and chamber volume of 81 mm<sup>3</sup> OD and 87 mm<sup>3</sup>  
84 OS (Figures 8-9). Optical coherence tomography measurements of lens vault along the horizontal  
85 meridian were 650 microns OD and 550 microns OS (Figures 10-11). Anterior chamber angle  
86 instrument-derived parameters are shown in Figures 12 and 13. High resolution scans of the anterior  
87 chamber angle found using the Spectralis supplemented these images by providing more confident

#### *Diplomate case 4: Primary angle closure*

88 visualisation of pertinent angle features, including: Schlemm's canal, the scleral spur and the ciliary  
89 body band (Figure 14).

90 Finally, standard automated perimetry was conducted (Figures 15-16). In the right eye, there was a  
91 cluster of reduced sensitivity superiorly that was statistically significant (five contiguous points of  
92 reduction, of which two points were  $p < 1\%$ ). The Glaucoma Hemifield Test was borderline and the  
93 pattern standard deviation result was identified as statistically significant (2.54 dB at  $p < 2\%$ ).

94 Although the fixation losses were flagged as outside the acceptable range ( $3/14 > 20\%$ ), the gaze  
95 tracker showed a steady gaze during the test. The left eye's result showed only two isolated points  
96 of reduction of low significance, with no other statistical anomaly.

97

#### 98 **DIFFERENTIAL DIAGNOSIS AND DIAGNOSIS**

99 Clinical guidelines utilise subtly different grading systems for the different stages of angle closure  
100 disease. The implication of such scales is that it constitutes a continuum or ordinal scale of  
101 progressive disease, with a break point where treatment is indicated. Therefore, the differentials for  
102 this presentation included:

- 103 • Open angle glaucoma suspect
- 104 • Open angles/open angle glaucoma
- 105 • Narrow and non-occludable angles
- 106 • Narrow and occludable angles
- 107 • Primary angle closure suspect
- 108 • Primary angle closure
- 109 • Primary angle closure glaucoma
- 110 • Secondary angle closure

111

112 Given that the angles were narrow or closed in most quadrants, open angle glaucoma disease was  
113 firstly ruled out, leaving the spectrum of angle closure disease. There was no pertinent medical  
114 history that would suggest a drug-induced angle closure (such as topiramate), and no other features  
115 in the anterior segment suggestive of masses that would be obstructing outflow (such as an iris  
116 cyst). As indentation gonioscopy revealed deeper structures within the angle, and common causes  
117 of synechiae or secondary mechanical closure such as neovascularisation at the angle or uveitis  
118 were also ruled out. Thus, the remaining differentials were: narrow but non-occludable angles,  
119 narrow and occludable angles, primary angle closure suspect, primary angle closure and primary  
120 angle closure glaucoma. The features of each of these conditions, as adapted from the Centre for  
121 Eye Health protocols and several publications are summarised in Table 1.

122

123 **Table 1:** Angle and other clinical features of angle closure spectrum disease<sup>15-17</sup>

<b>Angle status</b>	<b>Other clinical features</b>	<b>Diagnosis</b>
No iridotrabecular contact (pigmented trabecular meshwork seen) and fully open	No elevated intraocular pressure, no other anomalies of the angle, disc or fields	Open, normal angles
Iridotrabecular contact (pigmented trabecular meshwork not seen) in one or fewer quadrants	No elevated intraocular pressure, no other anomalies of the angle, disc or fields	Narrow but non-occludable angles
Iridotrabecular contact (pigmented trabecular meshwork not seen) in two quadrants	No elevated intraocular pressure, no other anomalies of the angle, disc or fields	Narrow and potentially occludable angles
Iridotrabecular contact (pigmented trabecular meshwork not seen) in three or more quadrants	No elevated intraocular pressure, no other anomalies of the angle, disc or fields	Primary angle closure suspect
Iridotrabecular contact (pigmented trabecular	One or both of: elevated intraocular pressure or	Primary angle closure

*Diplomate case 4: Primary angle closure*

---

meshwork not seen) in three or more quadrants	peripheral anterior synechiae; normal optic disc and fields	
Iridotrabecular contact (pigmented trabecular meshwork not seen) in three or more quadrants	One or both of: elevated intraocular pressure or peripheral anterior synechiae; plus glaucomatous disc and/or fields	Primary angle closure glaucoma

---

124

125 Using this diagnostic matrix, the patient at present fits into the category of primary angle closure  
126 suspect (no elevated intraocular pressure or synechiae seen; no glaucomatous disc and inconclusive  
127 visual field results), with both eyes appearing similarly. Given this stage of diagnosis, the patient  
128 was presented with two options, as per the current Australian guidelines for glaucoma management.  
129 Firstly, she could elect to be referred to a local ophthalmologist for evaluation. Secondly, she could  
130 elect to be referred internally to the Centre for Eye Health Glaucoma Management Clinic, which is  
131 a satellite clinic of the local health district ophthalmology department for onward referral for  
132 surgical treatment. The patient elected for the second option and was seen in the Glaucoma  
133 Management Clinic six days later with an attending ophthalmologist.

134 At the subsequent visit with the consulting ophthalmologist, the patient underwent repeat  
135 gonioscopy. The ophthalmologist agreed with the previous gonioscopic findings, and laser  
136 peripheral iridotomy versus lens extraction was discussed. Due to a combination of good vision,  
137 intraocular pressures within the normative range and minimal cataracts, laser peripheral iridotomy  
138 was preferred. She was referred for laser within the Prince of Wales Hospital Eye Clinic (a public  
139 hospital clinic) to be performed two weeks later, right eye first, left eye second.

140

141

142 **DISCUSSION**

143 **Definition and spectrum of angle closure disease**

144 Although the open-angle form of glaucoma is typically more common amongst all cases of  
145 glaucoma in many populations across the world, angle closure glaucoma is responsible for half of  
146 the cases of blindness due to glaucoma.<sup>1</sup> As with primary open angle glaucoma, primary angle  
147 closure is more common compared to secondary causes.<sup>18</sup> Also similar to open angle glaucoma,  
148 aspects of primary angle closure disease that have been debated include causation, natural history,  
149 classification and staging, the role of technologies and clinical techniques in the assessment, and  
150 treatment protocols, particularly in early disease.<sup>17, 19</sup> Specifically, understanding the spectrum of  
151 angle closure disease is important as it guides intervention and prognostication, similar to the  
152 manner in which open angle glaucoma is treated. Although many large scale, randomised clinical  
153 trials and meta-analyses are available for open angle glaucoma or ocular hypertension,<sup>20-23</sup> much  
154 less evidence is available for angle closure disease, in part due to the constraints by its clinical  
155 presentation.

156 One classification system that endeavours to provide a clinical guide for assessing potential  
157 progression and intervention by the stage of severity has been provided by Thomas and Walland,<sup>17</sup>  
158 modified from the International Society Geographical and Epidemiological Ophthalmology  
159 (ISGEO) classification. This system suggested five categories: normal, open angles; primary angle  
160 closure suspect; primary angle closure; primary angle closure glaucoma; and acute primary angle  
161 closure. The authors further provide a series of definitions for each of these categories of primary  
162 angle closure disease. A normal, open angle is defined as visibility of the posterior trabecular  
163 meshwork in two or more quadrants. A primary angle closure suspect status is defined by the  
164 authors as greater than or equal to 180 degrees of posterior trabecular meshwork not visible on  
165 gonioscopy. For both of these categories, a normal disc and normal intraocular pressure are

#### *Diplomate case 4: Primary angle closure*

166 required. As the angle closure disease becomes more advanced, with a greater degree to which the  
167 pigmented trabecular meshwork cannot be visualised and increased intraocular pressure, there is a  
168 corresponding increased risk of developing primary angle closure glaucoma. Of note, the authors  
169 have emphasised the importance of proper gonioscopic technique.<sup>19, 24</sup>

170 This particular scheme contrasts significantly with other clinical guidelines, and reflect the  
171 definitions used by primarily Australian and New Zealand ophthalmologist and optometrists. Other  
172 clinical guidelines may vary in terms of the cut-off visible structure. For example, the Asia Pacific  
173 Glaucoma Guidelines suggest visibility of the scleral spur in at least 180 degrees as the cut-off for  
174 open angles.<sup>25</sup> This may in part be due to the difficulty in distinguishing between the anterior and  
175 posterior trabecular meshwork in some patients. This may also be related to the American Academy  
176 of Ophthalmology guidelines, which merely state visibility of the “trabecular meshwork” as the cut-  
177 off, without separating the two layers.<sup>16</sup> The International Council of Ophthalmology guidelines are  
178 notably vague, with no clear separation of staging beyond stable or unstable glaucoma.<sup>26, 27</sup> Another  
179 staging system has been suggested by Sihota<sup>28</sup> in an attempt to amalgamate several different  
180 subtypes of angle closure disease into a simplified form, but yet this also suffers from the weakness  
181 of not necessarily being a continuum (see below for further discussion). All of the above systems  
182 state that the presence of synechiae is important, as it is suggestive of chronic appositional  
183 closure.<sup>29</sup> However, further commentary<sup>30</sup> has suggested differences between types of synechiae –  
184 high and low – which may indicate different stages of chronicity or phenotypes of angle closure  
185 disease. This requires further ongoing investigation.

186 Another important distinction is the intermediate stage of angle narrowing that lies between a  
187 completely open and normal angle and the primary angle closure suspect stage. For example, the  
188 American Academy of Ophthalmology guidelines suggest that non-visibility of the trabecular  
189 meshwork in three or more quadrants represents the discrete stage of primary angle closure suspect,  
190 and that non-visibility of two quadrants only represents a narrow but only potentially-occludable

*Diplomate case 4: Primary angle closure*

191 angle.<sup>16</sup> The question is: is the distinction between anterior and posterior trabecular meshwork  
192 important? This will be discussed more below.

193 Overall, these systems each have their own strengths and limitations, and these broadly reflect the  
194 current shortcomings of our understanding of angle closure disease. Firstly, there are  
195 inconsistencies regarding the stage denoting normal and open angles. The categorical system of  
196 Thomas and Walland<sup>17</sup> seems to imply that a normal angle can range anywhere from being wide  
197 open with ciliary body band seen to up to two quadrants with only posterior trabecular meshwork  
198 seen. However, could the range between ciliary body band and trabecular meshwork still indicate a  
199 spectrum with a progressively narrowing anterior chamber angle? This second description grading  
200 the anterior chamber angle appears to be more compatible with a disease with a spectrum of  
201 severity and facilitates titration of patient care with a changing clinical course. For example, with  
202 age-related ocular changes such as cataract progression, it is not uncommon to find decreased  
203 visibility of angle structures and narrowing of the chamber parameters,<sup>31</sup> and so being able to  
204 distinguish between a wide open angle (such as ciliary body band seen) with a borderline narrow  
205 angle (such as posterior trabecular meshwork barely seen) is important.

206 A second point of contrast is the inconsistency by which the trabecular meshwork is used as a cut-  
207 off for occludable angles. Guidelines seem to refer to this cut-off as either the posterior (pigmented)  
208 trabecular meshwork,<sup>25</sup> or simply as the trabecular meshwork.<sup>26</sup> Anatomically, the posterior  
209 trabecular meshwork seems to be a more logical structure attempt to visualise, as it represents the  
210 approximate location of Schlemm's canal.<sup>32</sup> One possible reason for limiting the description is the  
211 difficulty by which the layers are clinically distinguished, particularly in patients with no or  
212 minimal pigmentation of the trabecular meshwork.<sup>33</sup> A strategy for visualising Schlemm's canal is  
213 putting pressure against the angle to cause blood reflux through Schlemm's canal. This occurs  
214 physiologically because temporary occlusion of blood flow through the episcleral venous plexus  
215 means that outflow is also blocked in Schlemm's canal.<sup>34</sup> This sign may also be identified in some

#### *Diplomate case 4: Primary angle closure*

216 cases of ocular pathology. Nonetheless, even this technique may make it difficult to distinguish the  
217 trabecular layers. The result of using trabecular meshwork alone without specifying anterior or  
218 posterior is potentially a less conservative cut-off for determining angle closure. Though intuitive,  
219 no study to date has examined this.

220 Thirdly, a limitation of these systems is that they only state the gonioscopic findings with respect to  
221 the visible angle structures. One of the challenges in gonioscopy is discerning whether the non-  
222 visibility is due to apposition or due to an irregular iris contour. Indeed, although the iris is an  
223 important structure in recording gonioscopy results, it is not mentioned as a significant landmark in  
224 any of these grading systems. Specifically, the aetiology of progressively narrowing angles may be  
225 due to a variety of causes, one of which is a steepening of the iris contour, such as due to  
226 enlargement of cataracts. This represents another limitation of gonioscopy as a technique, as  
227 descriptions of the iris contour is limited to qualitative grades (flat, regular, steep, plateau), unlike  
228 the staging system used for the angle structures.

229 Further to the above, the gonioscopic grading appears inconsistent across test conditions. As  
230 mentioned, the lighting conditions for testing are critical for accurate determination of the angle.  
231 Alongside this, the pupil size is important: mydriatic conditions may also cause iridotrabecular  
232 contact even in cases where the angles appeared wide open at baseline or in relatively low-risk or  
233 normal patients.<sup>35-38</sup> However, few current clinical guidelines specifically state all of the conditions  
234 under which gonioscopy should be performed.<sup>16</sup>

235 Another major limitation of the grading schemes is that, unlike open-angle glaucoma, progression  
236 rates and treatment titration is unclear on the basis of the categorical scale, and that there is little  
237 robust evidence to guide best clinical practice. Instead, the recommended treatment paradigms and  
238 review schedules appear to mainly be driven by the risk of progression resulting from only a  
239 handful of small-scale studies,<sup>39-41</sup> none of which are particularly related to each other, thus making

240 extrapolation difficult. For example, the studies by Thomas et al<sup>39,40</sup> utilised a different definition  
241 of primary angle closure suspect compared to the study of Yip et al.<sup>41</sup> This will be further  
242 developed in the section below.

243

#### 244 **The natural history of angle closure spectrum disease**

245 As a corollary to the major limitations described above, the natural history of angle closure disease  
246 is poorly understood, again unlike primary open-angle glaucoma. One of the features of angle  
247 closure disease that makes it less conducive for measurement of progression is the discreteness of  
248 the scales used in measuring the anterior chamber depth to determine the degree of closure. In  
249 contrast, several of the parameters measured in primary open-angle glaucoma can be quantified and  
250 hence determination of progression or change is made easier; these include clinical features such as:  
251 cup-to-disc ratio, retinal nerve fibre layer thickness, ganglion cell-inner plexiform layer thickness,  
252 and visual field indices (mean deviation, pattern deviation and event analysis using visual field  
253 sensitivity).<sup>42,43</sup> There are a number of limitations to methods that suggest an ordinal value  
254 assignment for the discrete structures visible on gonioscopy (for example: 0 for Schwalbe's line and  
255 4 for ciliary body band). One of the potential barriers to standardisation of such an ordinal scale is  
256 the implication that the numerical values may be mistaken for a scalar unit: structures that are  
257 equidistant apart in terms of the stage of disease severity. Instead of resembling the scalar  
258 parameters used in open-angle glaucoma, the ordinal scale may instead bear more similarities to  
259 diseases like macular degeneration or cataract in which there are also ordinal, but not necessarily  
260 equidistant, scales.

261 Another problem with this scale is its clinical utility: at present, there is no clear advantage of using  
262 an ordinal scale, as final diagnostic determination is based on a complete view of the angle. In  
263 diseases such as macular degeneration, it is informative to use a scoring system for determining

*Diplomate case 4: Primary angle closure*

264 disease diagnosis, staging and prognostication (progression to late macular degeneration).<sup>44</sup> Again,  
265 because of the lack of understanding of the natural history of angle closure disease, such a scoring  
266 system would optimally require an associated level of risk for progression, for example, from grade  
267 3 to grade 2 in a quadrant representing a certain percentage increased risk of developing angle  
268 closure. An interesting analogy is in fact mean deviation in standard automated perimetry in open-  
269 angle glaucoma: although statistical software packages tend to analyse the results using a linear  
270 regression function, the actual natural history of visual field progression tends to be nonlinear  
271 instead.<sup>45</sup> Could the progression of stages of angle closure disease be nonlinear too? This also  
272 hearkens to the significant limitations of existing and widely used gonioscopy grading schemes (see  
273 below).

274 It is important to elicit the normal age-related change in the anterior chamber angle, and how the  
275 angle closure disease process overcomes this magnitude of change. Part of this involves  
276 understanding other age-related changes occurring in the eye that are related to the risk of angle  
277 closure. One of the most significant age-related changes in anterior segment morphology is in the  
278 crystalline lens, which thickens with age.<sup>46-48</sup> This then causes shallowing of the anterior chamber,  
279 with increased axial occupation by the lens, which is subsequently a risk factor for angle closure.  
280 Interestingly, age-related changes in axial length have been debated; instead, it appears that the  
281 crowding of the anterior segment plays a bigger role in angle closure disease.<sup>49-51</sup> Instead, one could  
282 question whether such changes are significant in the context of anterior segment changes. This  
283 hypothesis has been supported by the presence of angle closure disease in patients with high  
284 myopia<sup>52-54</sup> and long axial lengths.<sup>55</sup> Though the risk of angle closure decreases significantly with  
285 longer axial lengths, crowded anterior segment features still elevate the overall risk. Since corneal  
286 thickness and curvature do not change significantly with age, the shallowing of the anterior  
287 chamber depth appears mostly related to the crowding due to the crystalline lens.

288 Whilst the use of continuous variables are an attractive avenue to pursue in lieu of fixed  
289 gonioscopic grading schemes, the significant overlap between normal and disease groups precludes  
290 the routine clinical use of automated indices. Further study is required in this area.

291  
292 **Gonioscopy: a historical perspective and evolution of the technique**

293 Gonioscopy was first suggested in the late 1800s by Trantas.<sup>56</sup> Early reports of angle assessment  
294 using gonioscopy tended to focus on methods to maximise the view of the angle, such as through  
295 compression, lens tilt or gaze rotation. This was likely a product of the culture of having only  
296 pilocarpine available for glaucoma treatment, and hence a high threshold for a narrow angle,  
297 relative to the definitions of today.<sup>57, 58</sup> Thus, if at any time there were angles that were open on the  
298 gonioscopic view, then the angle was considered to be open.

299 More recently, there has been a shift towards structures visible only on primary gaze for staging  
300 angle narrowing, rather than manipulative gonioscopy.<sup>24</sup> Further to this, it became abundantly  
301 apparent that illumination conditions dramatically affect the angle appearance.<sup>59-62</sup> Such has the  
302 importance of correct conditions for gonioscopic evaluation been discussed that some have even  
303 raised suggestions of exploiting such conditions, such as light-dark changes or prolonged dark  
304 adaptation, as indices for angle closure or provocative testing.<sup>60, 63</sup> One example is the modified  
305 dark adaptation provocative test,<sup>63</sup> in which a patient is dark adapted for three minutes and has  
306 anterior segment imaging repeated; this test reportedly yields reasonable agreement and sensitivity  
307 compared to gonioscopy (notably, this study used anterior segment optical coherence tomography).

308 At present, gonioscopy remains the gold standard of viewing the anterior chamber angle and for  
309 determining its width and relevant signs for the purposes of grading angle closure spectrum  
310 disease.<sup>64</sup> However, the technique is not without its problems, and these are discussed below, with  
311 additional context of other imaging or testing modalities provided.

312

313 **Limitations of gonioscopy in clinical practice**

314 Although gonioscopy is the current gold standard for assessment of the anterior chamber angles, its  
315 clinical use is limited by the subjectivity of the technique. A number of named gonioscopy grading  
316 schemes currently exist and are used in practice to varying degrees, further confounding the  
317 subjectivity. The Shaffer system<sup>65</sup> describes angles from grade 0 to 4, depending on the width in  
318 degrees (0 to 35-45°). The interpretation of these extremes is that a grade of 0 means that the angle  
319 is closed in part or along the entirety of the circumference while a grade of 4 (or indeed 3) indicates  
320 an angle that is impossible to close. The Scheie system<sup>66</sup> describes angles from “wide” to “IV” (no  
321 structures visible). The Spaeth grading scheme<sup>58</sup> is one of the most complex grading systems. Its  
322 grade describes the insertion angle (structure; capital Roman letter: A, anterior to Schwalbe’s line;  
323 to E, extremely deep with >1 mm ciliary body band seen), the magnitude of the angle (in degrees),  
324 the configuration of the iris (small Roman letter: b, bowing anteriorly; p, plateau configuration; f,  
325 flat; c, concave) and the grade of the trabecular pigmentation. Depending on which scheme is used,  
326 there can be significant inconsistencies between clinicians and may be a source of variability in  
327 angle assessment in practice.

328 Instead of fixed grading schemes that are variably adopted in practice, a more practical  
329 recommendation may be to simplify the grading by listing out the pertinent features seen during the  
330 exam: the deepest visible structure, the amount of pigmentation and the contour of the iris. Thus,  
331 instead of relying upon numerical or arbitrarily nominal grades, the use of familiar nomenclature  
332 may be more conducive for clinical communication.

333 Aside from its mode of recording and correlation with stages of angle closure disease, a number of  
334 practical concerns regarding gonioscopy remain. With the advent of electronic patient records  
335 (ePR), there is another identifiable gap in clinical practice: how should one go from recording

336 gonioscopes to a written record card? Further to this, common ePRs used in optometry or  
337 ophthalmology may not have a specific section for anterior chamber angle assessment, nor one  
338 specifically for gonioscopy results. We have recently implemented a new ePR in our clinic  
339 specifically for patients undergoing glaucoma assessment, which provides directed forms for  
340 gonioscopic findings. Further improvements to this system could be the use of drop-down menus  
341 for consistency in record keeping.

342 However, before considering the implementation of consistent ePRs into clinical practice, there is  
343 the major issue of gonioscopy performed in routine clinical optometric practice. A number of  
344 studies have highlighted the relative infrequency at which gonioscopy is performed in private  
345 practice by optometrists and ophthalmologists, even across multiple health care contexts.<sup>67-74</sup> Many  
346 optometric registration boards demand a level of clinical competency that includes being able to  
347 perform gonioscopy as a requirement for registration, especially for more recent graduates for  
348 whom this represents a logical expansion of clinical practice. However, several barriers to  
349 gonioscopy have been cited, including: the lack of confidence, the lack of demand for such services,  
350 the lack of training and limited accessibility to equipment.<sup>72, 75</sup> Although gonioscopy is  
351 acknowledged to be an integral part of the glaucoma assessment, it is the skill that is least exercised  
352 by practicing optometrists. Additional training or certification processes to assist in this skill have  
353 been suggested, but the uptake appears to be limited to niche groups of optometrists. This is a  
354 significant problem that needs to be tackled from a number of practical directions.

355

#### 356 **Should gonioscopy remain as the gold standard? Comparison with other techniques**

357 Despite the above limitations, gonioscopy remains the current gold standard for anterior chamber  
358 evaluation. To overcome aspects of gonioscopy that limit its clinical use, several non-invasive  
359 techniques of measuring the angle have been suggested.

360

361 ***Limbal anterior chamber depth estimation by the van Herick technique***

362 One of the simplest screening methods is the limbal anterior chamber depth estimation, using the  
363 van Herick technique. Originally described by van Herick and colleagues in 1969,<sup>76</sup> the technique  
364 is: offsetting the slit lamp illumination arm by 60° temporally, using a bright, narrow beam directed  
365 perpendicularly to the ocular surface at the limbus and then comparing the depth of the peripheral  
366 anterior chamber depth to the thickness of the cornea. The result is a ratio or percentage, depending  
367 on nomenclature. The original grading scheme suggested by van Herick et al<sup>76</sup> consisted of four  
368 grades: less than 25%, 25%, greater than 25% and up to 50% and greater than 100%. Interestingly,  
369 this grading scheme did not include a grade for category 50-100%. This is because that particular  
370 study did not commonly find a gonioscopically occludable angle in patients with van Herick angle  
371 of >50%, and thus, for the purpose of screening for the risk of angle closure, such a grade was  
372 unimportant. Based on the original study, a screening cut-off of less than 25% was used for flagging  
373 patients at risk of angle closure.

374 Several cut-off values have been suggested for limbal anterior chamber depth. Foster et al.<sup>77</sup>  
375 examined three different cut-offs for van Herick ratios for their sensitivity and specificity. The  
376 traditional less than 20-25% cut-off has been found to have a sensitivity of 56-89% and a specificity  
377 of 89-99%, depending on the study.<sup>11, 78, 79</sup> A cut-off of less than or equal to 15% had a sensitivity  
378 of 84% and a specificity of 86%. A cut-off of less than or equal to 25% had a sensitivity of 99.2%  
379 and specificity of 65.5%.

380 Aside from the ease of use and widespread availability (one only needs a slit lamp), one of the  
381 originally documented strengths of van Herick is its high inter-observer reproducibility.<sup>11, 77</sup> (Foster  
382 et al 2000, Thomas et al 1996). As the temporal limbus is used as the screening angle of interest (it  
383 tends to be shallower compared to the nasal angle), this technique therefore relies on the limbal area

#### *Diplomate case 4: Primary angle closure*

384 being clear. Lesions like pterygium or corneal scarring can impeded the appearance of the limbal  
385 anterior chamber depth, representing a significant limitation of the technique. More interestingly,  
386 Javed et al.<sup>80</sup> provided commentary that borderline narrow angles presented a potential clinical  
387 conundrum. They found that van Herick grades 1 (less than 25%) and 4 (greater than 100%) were  
388 highly repeatable, grades 2 and 3 were not. While grade 3 is less problematic as it is unlikely going  
389 to be associated with an increased risk of angle closure, grade 2 can be considered to be borderline  
390 narrow. Perhaps a more liberal criterion such as less than or equal to 25% should be considered.

391 The high repeatability of the van Herick technique has been shown to be an advantage over  
392 gonioscopy ( $\kappa = 0.29$  compared to  $\kappa = 0.54$ ). As an initial screening method for narrow  
393 angles, van Herick appears to be superior to gonioscopy. This has been further examined by Jindal  
394 et al.<sup>81</sup> who examined the repeatability of limbal anterior chamber depth amongst optometrists and  
395 agreement with ophthalmologists. Two grading schemes were used: the traditional 4-point scale and  
396 the modified 7-point scale suggested by Foster et al.<sup>77</sup> Importantly, using both systems, very few  
397 cases of narrow angles were discordantly estimated amongst all observers, again reinforcing the  
398 application of van Herick as a screening technique. However, whilst the modified 7-point scheme  
399 appears to produce greater repeatability compared to the 4-point scheme, the practical implications  
400 of this is not known: does it actually impact upon the final patient management if both systems  
401 perform equally well in screening patients with narrow angles?

402

#### 403 ***Smith's test for anterior chamber depth***

404 Another non-invasive test that is readily performed on the slit lamp is Smith's test<sup>82</sup> for the anterior  
405 chamber depth. Proposed in 1979, the method is: horizontal slit beam, illumination arm positioned  
406 at 60° temporally, slit lamp system set at the optical axis of the eye in primary gaze, focus beam on  
407 the cornea (assisted with fluorescein as required), and then finally adjust the slit beam height until

#### *Diplomate case 4: Primary angle closure*

408 the blurred and focussed slit images are joined. The resultant slit beam height is multiplied by 1.31  
409 to obtain an estimate of anterior chamber depth in mm. Another application of Smith's test is in  
410 estimating sag depth for contact lens fitting. A recent study has suggested a Smith's test cut-off of  
411 less than 2.50 mm, which has a sensitivity of 76.5% and specificity of 70.5%.<sup>83</sup> Although this this is  
412 similarly non-invasive and accessible, the relatively poorer sensitivity and specificity compared to  
413 van Herick begs the question regarding its actual utility and additive nature.

414

#### 415 *Scheimpflug imaging*

416 This technique describes the change in the focal plane that occurs when a camera lens is tilted.  
417 Instead of having a flat focal plane (i.e. where the lens plane and film plane are aligned such that  
418 they are exactly parallel such as in normal cameras), the film plane is tilted, shifting the plane of  
419 sharp focus to the intersection point of the film and lens planes. This allows examiners to obtain slit  
420 images of the anterior segment of the eye that retain depth.<sup>84</sup>

421 This technique has shown promise as a non-invasive measurement technique for the anterior  
422 chamber. Rossi et al.<sup>85</sup> showed good diagnostic ability of the commercially available Pentacam  
423 using automated anterior chamber angle, depth and volume measurements to find occludable angles  
424 vs. normal open angles. However, their study had only a small number of subjects, and did not  
425 group occludable angles by severity level. The cut-offs suggested by Rossi et al.<sup>85</sup> are (AUROC in  
426 brackets): anterior chamber angle, 22.4° (0.94); anterior chamber depth (edge), 1.12 mm (0.91);  
427 anterior chamber depth (central), 1.93 mm (0.89); and anterior chamber volume, 84 mm<sup>3</sup> (0.89).

428 Grewal et al.<sup>86</sup> also examined Pentacam and anterior-segment optical coherence tomography  
429 parameters in open angle and narrow angle eyes. There were significant differences in both anterior  
430 chamber depth ( $2.70 \pm 0.38$  vs.  $2.06 \pm 0.38$ , in mm) and anterior chamber volume ( $146.5 \pm 35.5$  vs.  
431  $95.6 \pm 20.6$ , in mm<sup>3</sup>). However, there was significant overlap when considering the overall range of

#### *Diplomate case 4: Primary angle closure*

432 values that these could take. For anterior chamber depth, the ranges were 1.8-4.16 mm for open and  
433 1.59-2.86 mm for narrow angles. For ACV, the ranges were 76-248 mm<sup>3</sup> for open and 58-137 mm<sup>3</sup>  
434 for narrow angles. They used a final cut-off value of 2.45 mm for anterior chamber depth  
435 (sensitivity 89.3%, specificity 72.6%) and 113 mm<sup>3</sup> for anterior chamber volume (sensitivity 90%,  
436 specificity 88.2%).

437 Other studies have also shown similar overlap in the anterior segment parameters between normal,  
438 narrow angle and angle closure patients.<sup>87-89</sup> Arising from these overlaps, there have been a number  
439 of criticisms of Scheimpflug imaging for the angle. The technique does not allow detailed imaging  
440 of the angle structures of ciliary body as can be achieved by ultrasound micromicroscopy. It also  
441 does not permit detailed visualisation of neovascularization, peripheral anterior synechiae or other  
442 abnormalities of the angle. The reflectivity and photographic nature of the scan means that  
443 anatomical details within the angle may be lost, unlike in anterior-segment optical coherence  
444 tomography. Essentially, Scheimpflug imaging can only view the angle approach.

445

#### 446 ***Anterior segment optical coherence tomography***

447 Optical coherence tomography is a technique that uses low-coherence interferometry to obtain high-  
448 resolution images of the eye. The instrument generates 2- or 3-dimensional tomographic images by  
449 measuring the echo time delay of light back-scattered from ocular tissues. Light from a low  
450 coherence light source is split into two paths with a beam splitter directing it to two arms of an  
451 interferometer. Light reflectance is compared between that which is reflected by a mirror and that  
452 which is back-scattered by the ocular tissues. Complete travel of the light beam is called an A-scan,  
453 analogous to ultrasound using sound waves. These are then combined to produce a B-scan to give a  
454 more complete axial cross-section of the ocular tissues.

*Diplomate case 4: Primary angle closure*

455 Though optical coherence tomography for imaging the eye was first introduced in 1991,<sup>90</sup> it was not  
456 until 1994 when it was first introduced for the anterior segment.<sup>91</sup> Much later, instruments using a  
457 longer operating wavelengths (such as 1310 nm) have overcome issues with resolution and scan  
458 depth, as absorption of this wavelength by water is less than that typically used for retinal imaging  
459 (such as 860 nm).<sup>92</sup> At this wavelength, there is less scattering loss and greater penetration into the  
460 anterior segment tissue. Notably, several posterior eye imaging instruments such as the Cirrus or  
461 Spectralis use a shorter wavelength (840 nm), but have anterior lens modules that allow for imaging  
462 of the anterior segment. In the case of the Cirrus, an additional 60D lens means that anterior  
463 segment imaging can be obtained by overlapping the source and mirror images, allowing for a scan  
464 depth of 5.8 mm. The Spectralis permits anterior segment scans by sacrificing part of the corneal  
465 image.

466 One recent instrument that has a specifically longer wavelength are the Casia swept-source  
467 frequency domain optical coherence tomograph, allowing for a scan area of 16 x 16 mm and depth  
468 of 6 mm. The A-scan rate of 30,000 Hz allows for a three-dimensional reconstruction of the anterior  
469 segment. A summary of currently available commercially available instruments is provided  
470 below.<sup>93</sup> Axial resolution essentially refers to depth, while transverse resolution essentially refers to  
471 lateral resolution.

<b>OCT Type</b>	<b>Manufacturer</b>	<b>Optical Source</b>	<b>Axial resolution (optical)</b>	<b>Transverse resolution</b>	<b>Scan Speed (A-Scans per second)</b>	<b>Scan Depth</b>	<b>Maximum Scan Width</b>
Visante OCT	Carl Zeiss Meditec, Dublin, CA	SLD 1310 nm	18 $\mu$ m	60 $\mu$ m	2000	6 mm	16 mm
Slit Lamp OCT	Heidelberg Engineering, Heidelberg, Germany	SLD 1310 nm	<25 $\mu$ m	20-100 $\mu$ m	200	7 mm	15 mm
Cirrus OCT	Carl Zeiss Meditec,	SLD 840 nm	5 $\mu$ m	15 $\mu$ m	27,000	2 mm	6 mm

*Diplomate case 4: Primary angle closure*

Dublin, CA							
Spectralis OCT	Heidelberg Engineering, Heidelberg, Germany	SLD 820 nm	7 µm (optical)	20 µm	40,000	2 mm	6 mm
Optovue iVue	Optovue, Inc, Fremont, CA	SLD 840 nm	5 µm	15 µm	26,000	2–2.3 mm	13 mm
Nidek RS 3000	Nidek, Gamagori, Japan	SLD 880 nm	7 µm	15 µm	53,000	2 mm	8 mm
Revo NX	Optopol, Zawiercie, Poland	SLD 830 nm	5 µm	18 µm	110,000	2.4 mm	16 mm
CASIA SS-1000 OCT	Tomey Corporation, Nagoya, Japan	SS laser 1310 nm	10 µm	30 µm	30,000	6 mm	16 mm
Triton OCT	Topcon Corporation, Tokyo, Japan	SS laser 1310 nm	8 µm	30 µm	100,000	6 mm	12 mm

472

473 Some of the angle structures can be visualised on anterior-segment optical coherence tomography,  
 474 and many of its quantitative indices require accurate localisation of these points, including  
 475 Schwalbe’s line, the scleral spur and the ciliary body. Visibility of Schlemm’s canal is also  
 476 advantageous where possible. The nasal and temporal angles are easier to visualise compared to the  
 477 superior and inferior angles due to less interference from the eyelids.<sup>94,95</sup> However, there are many  
 478 cases where structures cannot be visualised.<sup>96</sup> Other potential errors and artefacts may result due to  
 479 anatomical or pathological features of the eye, such as arcus or pterygium. Quantitative assessment  
 480 of the angle using several parameters have been suggested (Table 2).<sup>97-99</sup>

481

Parameter	Definition
Anterior chamber width (ACQ)	Horizontal scleral spur-to-spur distance (mm)
Lens vault (LV)	Perpendicular distance between the anterior pole

*Diplomate case 4: Primary angle closure*

---

	of the crystalline lens and the horizontal line joining the two scleral spurs (microns)
Iris thickness (IT)	Measured at 750 microns or 2000 microns from the scleral spur; the radial distance from the scleral spur (microns)
Iris curvature (IC)	Draw a line from the most peripheral points to the most central point of the iris epithelium; then, draw a perpendicular line extended from this line to the point of greatest convexity: this is the iris curvature (in mm)
Anterior chamber area (ACA)	Cross sectional area of the anterior segment bounded by the corneal endothelium
Anterior chamber volume (ACV)	Vertical line drawn through the midpoint of the anterior chamber area which is then rotated 360° about this vertical axis to obtain volume in mm <sup>3</sup>
Angle opening distance (AOD) at 500 microns	Distance between the cornea and iris at 500 microns measured perpendicularly from the scleral spur (microns)
Trabecular iris space area (TISA)	The area of the trapezium from the AOD backwards into the scleral spur (microns <sup>2</sup> )
Angle recess area (ARA)	The triangular area between the trapezium of the trabecular iris space area in towards the angle

---

---

(microns<sup>2</sup>)

---

Trabecular-iris contact length (TICL)

The distance over which the iris is contacting the trabecular meshwork (in microns)

---

482

483 In light of the challenges facing determination of anterior segment parameters due to difficulties in  
484 visualising structures like the scleral spur, one interesting alternative has been proposed: the  
485 Schwalbe's line to iris distance (S-I distance), which is the shortest distance in microns between  
486 Schwalbe's line to the anterior border of the iris.<sup>100</sup> This has been shown to correlate reasonably  
487 well with Schaffer angle grades, but requires ongoing investigation and validation.

488 Although these parameters are important in angle closure, no firm cut-off values have been  
489 established at this stage. Wang et al.,<sup>99</sup> for example, showed only very small differences between  
490 iris thickness at 750 microns (0.476 versus 0.453 mm) and at 2000 microns (0.491 versus 0.482  
491 mm), for non-angle closure and angle closure patients, respectively. Even though there are  
492 statistically significant differences between the groups, overlap and the small clinical differences  
493 that could make these be difficult to reliably separate.

494

#### 495 ***Ultrasound biomicroscopy***

496 Ultrasound biomicroscopy has had a long history of use for anterior chamber angle assessment. The  
497 use of a higher frequency transducer allows reduced penetration depth to around 5 mm, but  
498 increases the resolution of the imaged structures, with lateral and axial resolutions estimated to be  
499 40 and 20 microns. In comparison to optical coherence tomography which uses light waves,  
500 ultrasound biomicroscopy uses sound waves for imaging the eye. This means that it is able to image  
501 the ciliary body, unlike optical coherence tomography.

#### *Diplomate case 4: Primary angle closure*

502 However, similar to optical coherence tomography, there are a number of limitations to ultrasound  
503 biomicroscopy, one of which is confusion as to where to put the apex of the angle when measuring  
504 it in degrees (at the level of the scleral spur, or at the level of the greatest angle depth).<sup>101</sup> Other  
505 factors that affect the ultrasound biomicroscopy measurement and interpretation include: variation  
506 in image acquisition (alignment on the eye, failure to control accommodation, failure to control  
507 room illumination and controlling the directions of gaze), image analysis (manual placement of  
508 measurement calipers, which may confound metric reproducibility), and the lack of widely accepted  
509 quantitative normative values of imaged structures such as the iris and ciliary body dimensions.  
510 This is even in the context of studies that suggest that diagnoses of plateau iris should be made with  
511 ultrasound biomicroscopy in the presence of an anterior positioned ciliary body.<sup>102</sup>

512

#### **513 Understanding angle closure disease pathophysiology using advanced imaging**

514 Angle closure disease is defined by the narrowing of the anterior chamber angle and eventual  
515 iridotrabecular contact, which then leads to increased intraocular pressure and optic nerve damage.  
516 Several anatomical locations have been highlighted as regions of interest in angle closure disease,  
517 and these have been subsequently used to differentiate subtypes of the disease.<sup>103</sup> Unlike open-angle  
518 glaucoma, in which the treatment tends to almost solely address intraocular pressure modification,  
519 angle closure disease has different avenues for therapy depending on the causative factor. As a  
520 result, adjunctive imaging technologies may assist in determining the most appropriate treatment for  
521 the individual patient.

#### **522 Pupil block angle closure**

523 Firstly, in the pupillary block aetiology, aqueous humour cannot pass from the posterior chamber to  
524 the anterior chamber due to iridolenticular touch.<sup>104</sup> The build up of pressure posterior to the iris  
525 causes anterior bowing of the iris at the angle, thus causing iridotrabecular contact. Importantly,

#### *Diplomate case 4: Primary angle closure*

526 pupillary block can coexist with other aetiologies of angle closure disease. Although it has been  
527 described to be the most common cause of angle closure disease, its therapeutic treatment, typically  
528 through the application of a laser peripheral iridotomy, frequently results in residual, chronic  
529 closure. In such cases, it becomes apparent that it is not the sole aetiology underpinning angle  
530 closure disease, and other differentials such as plateau iris, a phacomorphic component or other  
531 secondary retroiridal causes should be explored (see more below).

532 There is a constellation of anterior segment parameters used to describe the risk for pupil block.  
533 Parameters such as the anterior chamber depth and the angle width are common amongst a slew of  
534 techniques including gonioscopy. The advent of advanced imaging techniques such as optical  
535 coherence tomography have led to the development of alternative measurements such as the  
536 trabecular iris angle, angle opening distance and trabecular iris surface area. However, whilst these  
537 parameters may be useful in identifying patients at risk of angle closure disease, no single  
538 parameter is used for the diagnosis of pupil block as a solitary aetiology. This reflects one of the  
539 issues with considering pupil block in isolation, as it commonly coexists with other aetiologies of  
540 angle closure disease and only through the application of therapeutic intervention, such as  
541 peripheral iridotomy, can they be revealed.

542

#### ***Plateau iris configuration or syndrome***

544 Secondly, plateau iris is an anatomical variant of the iris where an anteriorly rotated ciliary body  
545 has occluded the ciliary sulcus, causing the peripheral iris to appear flat and in some cases appose  
546 the trabecular meshwork.<sup>105</sup> There are several signs that are commonly seen in plateau iris  
547 configuration in clinical practice. One sign is the characteristic hook-like insertion of the iris into  
548 the angle, and the otherwise flat iris plane towards the pupil. Interestingly, the angle width may  
549 range from wide open to the ciliary body to almost closed (apposition), depending on the patient.

#### *Diplomate case 4: Primary angle closure*

550 Notably, the anterior chamber depth is typically normal or deep, unlike some other types of angle  
551 closure. As mentioned above, it is common to find patients that have residual angle closure even  
552 after laser peripheral iridotomy, and the most common cause of this residual closure is plateau iris  
553 syndrome. Note that it is only referred to as “syndrome” if it follows unsuccessful initial treatment  
554 using iridotomy<sup>106</sup> (occurring in up to a third of patients<sup>107</sup>); the term “plateau iris configuration” is  
555 used if sufficient pupillary block is relieved with treatment.

556 One of the prime techniques used to visualise plateau iris configuration is ultrasound  
557 biomicroscopy. As light waves from optical coherence tomographs cannot penetrate the scleral or  
558 uveal tissue, the configuration of the ciliary body can be difficult to determine using such non-  
559 invasive techniques alone. Ultrasonography, on the other hand, produces sound waves that are able  
560 to penetrate into deeper tissue, at the cost of technique resolution. Despite its utility, ultrasound  
561 biomicroscopy has a number of limitations. Even though it is a relatively older technique in  
562 comparison to optical coherence tomography, it is likely less readily available. Part of this stems  
563 from the significant skill required to perform this technique. It is subject to substantial intra- and  
564 inter-individual variability, depending on factors such as application pressure, practitioner  
565 positioning and patient positioning. Specifically, the application of pressure and the direction of  
566 application – whether on- or off-axis – may affect the configuration of the ocular structures. For this  
567 reason, other options for imaging and diagnosing plateau iris are needed for more widespread  
568 clinical use.

569 Although optical coherence tomography has limitations in penetrating the ocular tissues to visualise  
570 the ciliary body, it is able to very readily image the iris-cornea-angle relationship. As one of the  
571 characteristic features of plateau iris is its distinctive hook-like shape of the iris as it enters the  
572 angle, optical coherence tomography is able to capture this information readily and with arguably  
573 greater repeatability in comparison to ultrasound biomicroscopy. From this, clinicians may be able  
574 to infer or strongly suspect a plateau iris configuration. Another potential iris sign is the flatness of

*Diplomate case 4: Primary angle closure*

575 the iris contour, with or without the presence of the double hump sign. Again, optical coherence  
576 tomography may be informative.

577

578 ***Lens-induced or phacomorphic angle closure***

579 Thirdly, lens-induced or phacomorphic angle closure occurs as a result of a large and thickened  
580 cataractous lens which pushes the peripheral and central iris forward.<sup>108</sup> Typically, the lens vault is  
581 increased due to the thickness of the iris, leading to pupil block and appositional closure.<sup>109, 110</sup> Due  
582 to potential differences in the location of lens thickening, this can overlap with pupil block and  
583 plateau iris causes. However, unlike uncomplicated plateau iris configuration, the anterior chamber  
584 depth tends to be shallow, corresponding to the increase in lens thickness.

585 The lens thickness may be difficult to visualise en face, and even with gonioscopy. The shadow test,  
586 the oblique orientation of a light source to the cornea, may be able to provide an impression of the  
587 iris contour and perhaps the degree of lens protrusion, but it is highly subjective and has poor  
588 repeatability. The use of anterior segment imaging can provide more precise measurements of the  
589 lens thickness, and, more importantly, the lens vault. The lens vault is defined as the perpendicular  
590 distance between the scleral chord and the anterior surface of the lens, and provides an impression  
591 of how much of an anterior shift there is of the lens, which may consequently increase crowding of  
592 the anterior chamber.<sup>111</sup> Given this, it would not be unusual to have a shallow anterior chamber  
593 depth, small anterior chamber volume and correspondingly narrow angle parameters.<sup>98, 112</sup>

594 Anterior segment imaging that reveals a contribution of the lens to angle closure disease may  
595 provide further support for cataract surgery as a treatment modality, rather than peripheral  
596 iridotomy. Following cataract surgery, the prediction is a reduction in lens vault and its other  
597 associated parameters.<sup>111</sup>

598

599 ***Atypical angle closure: ciliary body, aqueous misdirection or other space-occupying lesions***

600 Fourthly, atypical causes of angle closure occur posterior to the lens-iris diaphragm. Ciliary block,  
601 aqueous misdirection or other space-occupying lesions are rare causes of angle closure. In aqueous  
602 misdirection, also known as malignant glaucoma, the iris does not necessarily bow forward (unlike  
603 pupil block), and it is typically discovered following intervention which does not appear to relieve  
604 the iridotrabecular apposition.<sup>113-115</sup> In ciliary block or aqueous misdirection, aqueous fails to move  
605 from the posterior chamber to anterior chamber due to an obstruction such as the vitreous face  
606 (vitreous block) or ciliochoroidal swelling (effusion), leading to an increase in pressure posterior to  
607 the iris.<sup>115</sup> Ultrasound biomicroscopy is useful in these cases to examine the retroiridal space for  
608 uveal effusions or plateau iris. As mentioned above, there is value in ultrasound biomicroscopy in  
609 such cases in comparison to light-based instruments such as optical coherence tomography due to  
610 its increased tissue penetrance.

611 However, these anatomical classifications of angle closure do not account for mechanical pulling or  
612 attachment of the iris to the cornea: that which occurs in synechiael angle closure. Any process that  
613 leads to chronic iridotrabecular touch can propagate synechia formation, eventually potentially  
614 resulting in 360 degrees of complete closure. Specific, common causes of synechia formation  
615 include anterior uveitis and neovascular glaucoma. In these causes, inflammation and neovascular  
616 membrane cause contraction of the iris towards the cornea, respectively, thus leading to synechia  
617 formation.

618 It is evident from the above descriptions of the multifaceted pathophysiology of angle closure  
619 disease that imaging modalities play a significant role in determining the underlying aetiology and  
620 therefore guiding treatment. Due to the known limitations of each imaging technique, a multimodal  
621 imaging and diagnostic approach is typically recommended.

622

623 **Patient-tailored medicine using a Bayesian approach to disease diagnosis**

624 The process of diagnosis for the patient presented in the present case report illustrates the

625 consideration given to the role of imaging in combination with other standard clinical techniques.

626 With the initial van Herick and gonioscopy results showing angle closure disease, the application of

627 anterior segment optical coherence tomography highlighted areas of iridotrabecular contact in

628 regions where the scans were performed. The amount of lens vault and the iris curvature appeared

629 concordant with the lack of significant cataract in the slit lamp examination. In combination with

630 her normal visual acuities, this guided treatment towards laser peripheral iridotomy, rather than

631 cataract surgery (see further discussion below).

632 In the present case, both eyes had angle closure disease, so often the question is: which eye to treat

633 first? It is uncommon to treat both eyes simultaneously in non-glaucomatous or non-acute

634 presentations of angle closure, much like chronic open angle glaucoma. In cases of pre-

635 glaucomatous or borderline disease, often the eye that exhibits a greater amount of closure is treated

636 first. In the present case, there was no eye preference due to relative symmetry.

637

638 ***To treat, or not to treat: considerations of asymptomatic disease***

639 One of the features common between open angle and angle closure disease is that they can be

640 asymptomatic. Treatment in most cases is to prevent further structural or functional loss. There

641 appears to be a paradigm shift towards earlier detection and intervention, whereby patients with

642 structural anomalies without necessitating function may also undergo treatment.

643 In angle closure disease, this translates to potentially earlier treatment prior to the onset of primary

644 angle closure, in which there is elevated intraocular pressure and/or synechiae formation, or primary

*Diplomate case 4: Primary angle closure*

645 angle closure glaucoma, in which there is obvious glaucomatous damage. Though aggressive  
646 treatment of the stages of angle closure leading up to chronic and irreversible structural changes  
647 may be warranted and recommended in many jurisdictions, the evidence for this should be carefully  
648 considered.

649 There are few natural history studies of angle closure disease, and it is unlikely that ethical approval  
650 would be provided for a large enough clinical trial to monitor patients with angle closure suspect  
651 status on no or sham treatment. If considering one of the few pieces of evidence available for  
652 examining the progression from primary angle closure suspect to primary angle closure, it appears  
653 the only 22% of patients will progress from the former to the latter stage in a five year period.<sup>39</sup>  
654 None of the patients developed blindness, primary angle closure glaucoma or acute primary angle  
655 closure. In another report on the same cohort, it was found that 28.5% of patients with primary  
656 angle closure progressed to primary angle closure glaucoma over five years.<sup>40</sup> Notably, this  
657 definition of primary angle closure suspect status was non-visibility of the pigmented trabecular  
658 meshwork in over 180° (two quadrants). This definition is significant: it is more sensitive than the  
659 three quadrant criteria used by some reports, but is less specific, meaning that potentially patients  
660 who may never have progressed to primary angle closure could have been included in the study,  
661 thereby lowering the overall progression rate figure. If we therefore consider the progression from  
662 primary angle closure suspect to glaucoma, this means that only 6.3% of patients had progressed  
663 from the former to the latter.

664 These progression rates may also be dependent upon ethnicity (discussed further below). A study in  
665 predominantly white Caucasian patients by Wilensky et al.<sup>116</sup> showed an overall risk of progression  
666 from primary angle closure suspect to primary angle closure of 19% over three years.

667 In another study by Yip et al.,<sup>117</sup> they reported a proportion of progression from normal open angles  
668 to primary angle closure suspect status of 20.4% over a six year period. This figure appears quite

*Diplomate case 4: Primary angle closure*

669 high overall, but there are several points of interest with respect to the study population. One  
670 notable point of interest is in the study name itself: this population was high risk – a Mongolian  
671 population. It would therefore be expected that the rate of progression is higher. Another point of  
672 interest is that they defined normal as pigmented trabecular meshwork in two or more quadrants, as  
673 per the International Society Geographic and Epidemiology Ophthalmology definition. Again, this  
674 relates back to a problem inherent in this definition: patients with ciliary body band visible in those  
675 same quadrants are regarded as the same as those with pigmented trabecular meshwork visible only.  
676 Currently, the American Academy of Ophthalmology has summarised the overall risk of conversion  
677 to approximately 25% over five years.<sup>16</sup> This figure can then be suitably titrated depending on their  
678 individual risk factors.

679 Although the majority of patients do not exhibit eventual progression from primary angle closure  
680 suspect to primary angle closure glaucoma or acute primary angle closure, those that do tend to  
681 have more visually devastating consequences. Thus, there appears to be a compelling reason to treat  
682 such patients. The question remains though: leading up to the point of primary angle closure suspect  
683 status, when should intervention be suggested, given this paradigm of early detection and  
684 treatment?

685

686 ***Risk factor analysis for guiding management***

687 As alluded to above, there are populations that are notably more high risk compared to others for  
688 developing angle closure disease, and these may provide additional guidance for the point of  
689 intervention. Several risk factors have been identified. Generally well-accepted demographic risk  
690 factors for angle closure disease include: older age, family history, female sex, and Asian/Inuit  
691 ethnicity.<sup>118-121</sup> These risk factors have a biological basis, as these groups represent those with  
692 smaller general ocular biometry, and hence greater risk of anterior segment crowding.

*Diplomate case 4: Primary angle closure*

693 Previous suggestions have also included hyperopia as a risk factor for angle closure disease.<sup>122, 123</sup> A  
694 hyperopic refractive error is an attractive target, as it is relatively simple to screen in comparison to  
695 other modalities such as anterior chamber angle assessment. The initial rationale for hyperopia as a  
696 risk factor for angle closure disease was that it may be associated with a shorter axial length and  
697 hence smaller overall ocular biometry. There are a number of flaws with this assumption.  
698 Hyperopia, like any refractive error, may be driven by both axial and refractive causes; the latter is  
699 probably unlikely to affect ocular biometry. Hyperopia also tends to be more common in those with  
700 smaller ocular biometry anyway, and hence it may be an epiphenomenon, rather than a direct risk  
701 factor for angle closure disease.<sup>52, 124, 125</sup>

702 One of the most compelling arguments against hyperopia as a risk factor is the steady prevalence  
703 and incidence of angle closure disease in high risk populations such as Asian ethnic groups despite  
704 the concurrent myopia epidemic.<sup>54</sup> If hyperopia were the cause, myopia should be relatively  
705 protective against angle closure disease and hence there should be a decline in the prevalence and  
706 incidence. Instead, it appears that although the prevalence of myopia is increasing in the at risk  
707 populations, the steady angle closure disease prevalence has been driven by ocular biometric  
708 parameters of the anterior segment remaining small and crowded. Thus, the current thinking is that  
709 hyperopia may be an epiphenomenon, rather than a direct risk factor for angle closure disease.

710 As mentioned above, the development of cataracts appears to be a risk factor for glaucoma.  
711 Although it may be related to ageing, its role in the phacomorphic aetiology of angle closure  
712 suggests a larger contribution of cataracts, in comparison to hyperopia.

713 Another widely-cited risk factor for angle closure disease is Asian ethnicity when considered  
714 relative to Caucasian or African American races. Numerous epidemiological studies have shown  
715 that Asian eyes typically have narrower angles – considered at risk of closure – and rates of  
716 blindness due to angle closure glaucoma tend to be higher in these groups. An important

#### *Diplomate case 4: Primary angle closure*

717 consideration is an ethnically-diverse population with a large subset of Asian patients. More  
718 relevant to certain parts of the world, and far more rare in Australia, is the Eskimo or Inuit ethnic  
719 group, which has been suggested to be the highest risk group.<sup>126, 127</sup> The main mechanistic factors  
720 behind these ethnic groups having greater risk is likely related to ocular biometry. However, this  
721 distinction has also led to a very interesting discussion on the evolutionary aspects of angle closure  
722 disease.<sup>128</sup>

723

#### **724 Management of angle closure spectrum disease**

725 As mentioned above, though the majority of patients without glaucomatous change or those with  
726 few risk factors for conversion to late stage disease may not eventually progress, the consequences  
727 of angle closure tend to be more dire and acute in comparison to chronic open angle glaucoma. As  
728 such, patients with earlier stages of the disease may still undergo prophylactic treatment. Typically,  
729 modern treatment of angle closure can be divided into two main interventions: laser peripheral  
730 iridotomy or lens extraction. Additionally, some patients may be candidates for laser peripheral  
731 iridoplasty.

732 A management algorithm that has been suggested broadly divides patients into two main categories:  
733 pre-presbyopic without cataracts, who would be more suitable for laser peripheral iridotomy; and  
734 presbyopic with cataracts, who may benefit more from lens extraction. However, these are  
735 guidelines only, and should also be tailored to the individual patient.

736

#### **737 *Laser peripheral iridotomy***

738 In laser peripheral iridotomy, a laser is used to create an opening in the peripheral iris, creating a  
739 passageway between the anterior and posterior chambers.<sup>129</sup> The laser is typically placed in the

#### *Diplomate case 4: Primary angle closure*

740 superior aspect of the iris, a short distance away from the limbus. A recent study has suggested  
741 placing the hole at the temporal positions instead,<sup>130</sup> but this has been highly debated,<sup>131</sup> with no  
742 conclusive evidence of greater reduction in dysphotopsia using this method.<sup>132, 133</sup> More recently, an  
743 inferior placement of the iridotomy has been suggested.<sup>134</sup>

744 Typically, iris crypts are targeted to reduce the difficulty in producing a patent iridotomy. In light  
745 irises, it is typically conducted using a neodymium:yttrium-aluminium-garnet (Nd:YAG) laser  
746 using the following settings: power, 4-8 mJ; pulses per burst, 1-3; fixed spot size. However, in  
747 darker irises, more energy is typically required, and it is not unusual to firstly pre-treat using an  
748 argon laser to create a crypt. In this procedure, sequential argon laser is performed. Firstly, the  
749 anterior border of the iris is removed (power, 300-400 mW; duration, 0.05 s; spot size 50-100 mm).  
750 Then, the iris stroma is removed (power, 900 mW; duration, 0.03-0.04 s; spot size 50 mm). The  
751 Nd:YAG laser is then used to remove the iris pigment epithelium (power, 1.7-3 mJ; pulses per  
752 burst, 2; spot size, fixed).<sup>135-138</sup> The goal is for iris pigment to be released and the aqueous and  
753 anterior capsule to be visible. There are different recommendations for iridotomy size, ranging from  
754 at least 200 microns to 500 microns in size.<sup>139, 140</sup> More evidence is required in this area.

755 Laser peripheral iridotomy is generally considered to be safe. Some potential complications of the  
756 procedure include: postoperative intraocular pressure spike, intraocular inflammation (anterior  
757 uveitis), iris bleeding and hyphema, focal cataract, posterior synechiae, visual symptoms (such as  
758 haloes around lights and glare) and local corneal decompensation. To prevent postoperative  
759 intraocular pressure spike due to acute inflammation and pigment liberation, topical intraocular  
760 pressure lowering medication is usually prescribed for short-term therapy (brimonidine or  
761 apraclonidine).<sup>141, 142</sup> Short-term topical steroids (such as prednisolone acetate) may be used to  
762 reduce anterior uveitis or peripheral synechiae due to the release of prostaglandins in the anterior  
763 chamber.<sup>143, 144</sup> Iris bleeding or a small hyphema are common following Nd:YAG, as it is a  
764 photodisruptive device.<sup>145</sup> It can be controlled by applying pressure in the globe. Again, this is

#### *Diplomate case 4: Primary angle closure*

765 transient. Focal cataracts or lens dislocation can develop if the iridotomy site is too close to the  
766 pupil, and can be due to excessive heat from argon laser or from direct tissue disruption from the  
767 Nd:YAG laser.<sup>146, 147</sup> There may be a similar mechanism behind local corneal decompensation and  
768 oedema.<sup>148</sup>

769 One of the more common complications of iridotomy is the occurrence of visual symptoms,  
770 reported in approximately 5-10% of patients.<sup>149</sup> These can be visually disturbing and take a number  
771 of different forms, including: shadows, ghosting, linear dysphotopsia, haloes, glare or diplopia. The  
772 risk factors such as iridotomy placement, coverage and size, for resultant dysphotopsia have been  
773 debated. For example, Spaeth et al.<sup>150</sup> showed that patients with partially covered or fully exposed  
774 iridotomies have a greater incidence of visual disturbances. As mentioned above, Vera et al.<sup>130</sup>  
775 suggested that temporal placement of the iridotomy may result in fewer disturbances, due to fewer  
776 aberrations with no tear meniscus present. On the other hand, Congdon et al.<sup>151</sup> showed no  
777 significant effect of any of these risk factors. This remains a subject of considerable debate and is  
778 dependent upon the individual surgeon.

779 Laser peripheral iridotomy has largely replaced surgical iridectomy.<sup>152</sup> As it is less invasive, such as  
780 reducing the effects on the corneal endothelium, iridotomy tends to be preferred, at least in the  
781 initial phase. However, iridectomy may still play a role in later stage disease, if manipulations of the  
782 ciliary body are also required to further reduce intraocular pressure.

783 Another type of laser surgery is laser peripheral iridoplasty.<sup>153</sup> This has been shown to be a niche  
784 procedure suggested for a subset of patients with persistent angle closure or iridotrabecular contact  
785 following laser peripheral iridotomy.<sup>154</sup> In this procedure, the iris stroma is debulked using an argon  
786 laser to reduce the thickness of the peripheral iris and to cause contraction of iris tissue away from  
787 the cornea, thereby reducing synechiae formation.<sup>155, 156</sup> This procedure has had good success in

#### *Diplomate case 4: Primary angle closure*

788 some studies,<sup>157-163</sup> but minimal effect in others.<sup>155</sup> However, it may be an option in patients who  
789 are pre-presbyopia and without cataracts to have a surgical-sparing treatment.

790

#### 791 ***Lens extraction***

792 Lens extraction is suggested in cases of patients where the phacomorphic component is significant  
793 or if the patient is presbyopic or has significant cataracts. Unlike laser peripheral iridotomy, lens  
794 extraction significantly alters the anterior segment biometry, which, as mentioned above, has  
795 implications for future progressive risk of angle closure.<sup>164, 165</sup> By removing the contribution of the  
796 lens bulk within the anterior segment, the iris naturally moves posteriorly, thus resulting in deeper  
797 anterior chamber depth, increased anterior chamber volume and widening of the anterior chamber  
798 angle. Notably, this will not alter the iris parameters.

799 Aside from typical potential complications in intraocular surgical procedures, one adverse effect of  
800 lens extraction is the loss of accommodation in the pre-presbyopic eye. Correction of refractive  
801 error can be a benefit to some patients with high refractive errors.<sup>166, 167</sup>

802

#### 803 ***Evidence-based treatment***

804 Unlike chronic open angle glaucoma, there are few large clinical trials that have examined the  
805 efficacy of these treatments in preventing further glaucomatous damage or progression of angle  
806 closure spectrum disease. Two landmark clinical trials are the EAGLE study<sup>168</sup> and the Zhongshan  
807 Angle-closure Prevention (ZAP) Trial.<sup>169</sup> The initial reports of these trials have now been reports.  
808 In the ZAP trial,<sup>169</sup> 775 Chinese patients aged 50-70 years diagnosed as primary angle closure  
809 suspect (less than 180 degrees of pigmented trabecular meshwork visible) underwent laser

*Diplomate case 4: Primary angle closure*

810 peripheral iridotomy in one eye and were followed for 18 months. A number of interesting results  
811 have been reported.<sup>170</sup> Firstly, around a quarter of eyes had persistent angle closure after iridotomy.  
812 Secondly, at two weeks after laser, the angle width of treated eyes increased significantly. However,  
813 after around 6 months, the angle width began narrowing in the treated eye, though at a slower rate  
814 in comparison to the control group. Thus, a longer trial is required to better understand the long-  
815 term prognosis following treatment.

816 Other trials in high risk populations (Mongolia and India) have suggested benefits of laser in terms  
817 of reducing the risk of acute angle closure attacks. Though synechiae may still develop following  
818 treatment, no patients in either study experienced an acute angle closure attack or glaucomatous  
819 changes.

820 The EAGLE study<sup>168</sup> on the other hand examined the role of early lens extraction for treatment of  
821 primary angle closure glaucoma. The patient cohort was slightly different<sup>171</sup>: phakic patients 50+  
822 years old with no evidence of cataract, with primary angle closure with intraocular pressure greater  
823 than 30 mmHg or primary angle closure glaucoma with intraocular pressure greater than 21 mmHg in  
824 at least one measurement, and without advanced glaucoma (mean deviation less than -15 dB and  
825 cup-disc ratios of less than 0.9). In this study, patients were randomised to clear lens extraction  
826 (note that patients were phakic and had no significant cataract) or laser peripheral iridotomy in  
827 order to compare the two treatment modalities. Other interventions were permitted to be performed  
828 as required in order to reach a target pressure of 15-20 mmHg, or for rescue.

829 There were numerous outcomes measures for this study. The clear lens extraction group had higher  
830 quality of life scores. They also had lower intraocular pressures (by approximately 1.3 mmHg) at 36  
831 months when compared to the laser peripheral iridotomy. Fewer additional treatments (drops,  
832 incisional glaucoma surgery) were required for the patients who had undergone cataract surgery  
833 compared to the laser group. Lens extraction was more expensive, on average, compared to

*Diplomate case 4: Primary angle closure*

834 peripheral iridotomy (\$3154 versus \$1900). This represented potential increased cost-effectiveness  
835 with lens extraction over iridotomy.<sup>172</sup> There was a slight difference in level of visual acuity  
836 favouring lens extraction, but visual fields were similar.

837 Overall, the results of the EAGLE trial reinforce the role of lens extraction. The results reveal  
838 interesting conditions under which lens extraction may be useful. Firstly, patients with angle closure  
839 disease with elevated intraocular pressure appear to benefit from lens extraction. Secondly, where  
840 lens extraction may be useful in other situations, such as in high refractive errors or significant  
841 cataract where patients may benefit from improved vision. Finally, where there is a significant  
842 phacomorphic component or an imminent phacomorphic component, then the patient may benefit  
843 from lens extraction instead of beginning first with a laser peripheral iridotomy.

844 When this evidence is applied to the present case, arguments could be made for either iridotomy or  
845 cataract surgery. Arguments for cataract surgery included early onset cataracts, moderate hyperopic  
846 refractive and her age (already minimal to no accommodation left). However, arguments against  
847 lens extraction include her relatively minimal cataracts, her good vision, the lack of a clear  
848 phacomorphic component and the intraocular pressure was within normal limits. One important  
849 consideration is the acceptance by the patient: are they amenable to undergoing surgery at this stage  
850 or not? In this particular case, the patient elected for laser peripheral iridotomy at present, as she felt  
851 that her vision was still acceptable. Another consideration is cost: in this particular case, as she was  
852 a public hospital system patient, iridotomy represented the more cost-effective option in the short-  
853 term.

854

855 **CONCLUSIONS**


856 Angle closure spectrum disease can potentially be more devastating than open angle glaucoma. The  
857 careful assessment of patients using a slew of anterior chamber angle examination techniques is

*Diplomate case 4: Primary angle closure*

858 required to diagnose, stage and prognosticate the disease. Current treatments are guided primarily  
859 by gonioscopic findings and historical risk factors. In time, there may be a paradigm shift towards  
860 utilisation of advanced imaging modalities to complement this examination process. Two main  
861 treatment options are available, and the results of long-term clinical trials are eagerly awaited to  
862 provide more guidance for optimal patient management.

863

864




865

866 **Figure 1:** Colour fundus photographs of the posterior pole of the right and left eyes (Kowa nonmyd  
867 7, Kowa Medical, Sendai, Japan)

868

Diplomate case 4: Primary angle closure




869

870 **Figure 2:** Optical coherence tomography of the optic nerve head and retinal nerve fibre layer for  
 871 right and left eyes (Cirrus HD-OCT, Carl Zeiss Meditec, Dublin, CA).

872

Diplomate case 4: Primary angle closure




873

874 **Figure 3:** Ganglion Cell Analysis printout (ganglion cell-inner plexiform layer thickness) for right  
 875 and left eyes (Cirrus HD-OCT, Carl Zeiss Meditec, Dublin, CA).

876

877



878

879 **Figure 4:** Superior and inferior goniophotographs of the right eye (G4, Volk Optical, Inc., Mentor,  
880 OH) taken under dim illumination settings (10% neutral density filter, no peripheral flash, 10%  
881 illumination, 16x magnification, ISO 200, aperture 2; BX 900 and Canon 50D, Haag Streit AG,  
882 Koeniz, Switzerland and Canon, Inc., Tokyo, Japan).

883

884



885

886 **Figure 5:** Nasal and temporal goniophotographs of the right eye, as per Figure 4.

887

888

889



890

891 **Figure 6:** Superior and inferior goniophotographs of the left eye, as per Figure 4.

892

893


894



895

896 **Figure 7:** Nasal and temporal goniophotographs of the left eye, as per Figure 4.

897




898

899 **Figure 8:** Scheimpflug imaging of the anterior segment of the right eye (Pentacam HR, Oculus Inc.,  
 900 Wetzlar, Germany). The 4 Maps Chamber printout was examined as it shows the distribution of  
 901 anterior chamber depth across the anterior segment (approximately 8 x 8 mm radius).

902

903

Diplomate case 4: Primary angle closure



904

905 **Figure 9:** Scheimpflug imaging of the anterior segment of the left eye, as per Figure 8.

906

907

Diplomate case 4: Primary angle closure

Name: \_\_\_\_\_ OD ZEISS

ID: \_\_\_\_\_ Exam Date: \_\_\_\_\_ CZMI




DOB: \_\_\_\_\_ Exam Time: \_\_\_\_\_

Gender: \_\_\_\_\_ Serial Number: \_\_\_\_\_

Technician: Operator, Cirrus Signal Strength: N/A

---

**Anterior Chamber Analysis : Anterior Chamber** OD  OS

ACT Measurements	Value
Central Corneal Thickness	558 µm
Angle to Angle Distance	11.17 mm
Lens Vault	650 µm
Anterior Chamber Depth	2.17 mm
Chamber Measurement	Value
Area	15.34 mm <sup>2</sup>

---

Comments

Analysis Edited: 12/07/2018 9:55 AM

Doctor's Signature \_\_\_\_\_

CFEH-CL-D03  
SW Ver: 10.0.0.14618  
Copyright 2016  
Carl Zeiss Meditec, Inc  
All Rights Reserved  
Page 1 of 1


908

909 **Figure 10:** Anterior segment optical coherence tomography Anterior Chamber Analysis results for  
 910 the right eye (Cirrus HD-OCT, Carl Zeiss Meditec, Dublin, CA). Note that the horizontal spur-to-  
 911 spur chord was generated manually, with the anterior chamber depth and lens vault inferred from  
 912 this value.

913

914

Diplomate case 4: Primary angle closure



915

916 **Figure 11:** Anterior segment optical coherence tomography Anterior Chamber Analysis results for  
 917 the left eye, as per Figure 10.


918

919


Diplomate case 4: Primary angle closure

Name: \_\_\_\_\_ OD   
 ID: \_\_\_\_\_ Exam Date: \_\_\_\_\_ CZMI  
 DOB: \_\_\_\_\_ Exam Time: \_\_\_\_\_  
 Gender: \_\_\_\_\_ Serial Number: \_\_\_\_\_  
 Technician: Operator, Cirrus Signal Strength: N/A

Wide Angle To Angle Analysis : Wide Angle To Angle  OD  OS



IC Measurements	Left	Right
AOD500	0.29 mm	0.35 mm
AOD750	0.39 mm	0.50 mm
TISA500	0.09 mm <sup>2</sup>	0.10 mm <sup>2</sup>
TISA750	0.18 mm <sup>2</sup>	0.21 mm <sup>2</sup>
SSA	30°	35°



Comments  Analysis Edited: 16/10/2018 15:02	Doctor's Signature _____	CFEH-ST-D06 SW Ver: 10.0.0.14618 Copyright 2016 Carl Zeiss Meditec, Inc All Rights Reserved Page 1 of 1
---	-----------------------------	--

920

921 **Figure 12:** Anterior segment optical coherence tomography Wide Angle to Angle results for the  
 922 right eye (Cirrus HD-OCT, Carl Zeiss Meditec, Dublin, CA). The areas of interest were manually  
 923 segmented to generate the numerical outputs.

924


925

Diplomate case 4: Primary angle closure


Name: OS  
 ID: Exam Date: CZMI  
 DOB: Exam Time:  
 Gender: Serial Number:  
 Technician: Operator, Cirrus Signal Strength: N/A



Wide Angle To Angle Analysis : Wide Angle To Angle OD  OS



IC Measurements	Left	Right
AOD500	0.16 mm	0.22 mm
AOD750	0.29 mm	0.37 mm
TISA500	0.04 mm <sup>2</sup>	0.06 mm <sup>2</sup>
TISA750	0.10 mm <sup>2</sup>	0.13 mm <sup>2</sup>
SSA	18°	23°



Comments: Analysis Edited: 16/10/2018 15:03

Doctor's Signature: \_\_\_\_\_

CFEH-ST-D06  
 SW Ver: 10.0.0.14618  
 Copyright 2016  
 Carl Zeiss Meditec, Inc  
 All Rights Reserved  
 Page 1 of 1

926

927 **Figure 13:** Anterior segment optical coherence tomography Wide Angle to Angle results for the  
 928 left eye, as per Figure 12.

929

930

Diplomate case 4: Primary angle closure


Overview Report  
SPECTRALIS® Tracking Laser Tomography



Patient:  
Patient ID:

DOB:  
Exam.:

Sex:



931

Software Version: 6.9.5

www.HeidelbergEngineering.com


Overview Report, Page 1

932 **Figure 14:** High resolution anterior segment optical coherence tomography of the angles (1 ACA  
933 scan, Spectralis OCT, Heidelberg Engineering, Heidelberg, Germany) for the nasal and temporal  
934 angles of right and left eyes. Note that the higher resolution allows more confident visualisation of  
935 Schlemme's canal, the scleral spur and ciliary body, in comparison to Figures 10-13.

936

937

Diplomate case 4: Primary angle closure




938

939 **Figure 15:** Standard automated perimetry results of the right eye (Humphrey Field Analyzer, 24-2  
 940 test grid, SITA-Standard; Carl Zeiss Meditec, Dublin, CA).

941

942

Diplomate case 4: Primary angle closure



© Carl Zeiss Meditec Inc., 2017. All rights reserved.

943

944 **Figure 16:** Standard automated perimetry results of the left eye, as per Figure 15.

945

946

*Diplomate case 4: Primary angle closure*

947 References:

- 948 1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. *Br J*  
949 *Ophthalmol* 2006;90:262-7.
- 950 2. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and  
951 projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology*  
952 2014;121:2081-90.
- 953 3. He M, Foster PJ, Johnson GJ, Khaw PT. Angle-closure glaucoma in East Asian and European  
954 people. Different diseases? *Eye (Lond)* 2006;20:3-12.
- 955 4. Yip JL, Foster PJ. Ethnic differences in primary angle-closure glaucoma. *Curr Opin Ophthalmol*  
956 2006;17:175-80.
- 957 5. Cho HK, Kee C. Population-based glaucoma prevalence studies in Asians. *Surv Ophthalmol*  
958 2014;59:434-47.
- 959 6. *The Glaucomas* Vol. 2. St Louis, MO: Mosby; 1989.
- 960 7. Whiteman AL, Klauss G, Miller PE, Dubielzig RR. Morphologic features of degeneration and cell  
961 death in the neurosensory retina in dogs with primary angle-closure glaucoma. *Am J Vet Res* 2002;63:257-  
962 61.
- 963 8. Ang LP, Aung T, Chua WH, Yip LW, Chew PT. Visual field loss from primary angle-closure  
964 glaucoma: a comparative study of symptomatic and asymptomatic disease. *Ophthalmology* 2004;111:1636-  
965 40.
- 966 9. Foster PJ, Baasanhu J, Alsbirk PH, Munkhbayar D, Uranchimeg D, Johnson GJ. Glaucoma in  
967 Mongolia. A population-based survey in Hovsgol province, northern Mongolia. *Arch Ophthalmol*  
968 1996;114:1235-41.
- 969 10. Salmon JF, Mermoud A, Ivey A, Swanevelder SA, Hoffman M. The prevalence of primary angle  
970 closure glaucoma and open angle glaucoma in Mamre, western Cape, South Africa. *Arch Ophthalmol*  
971 1993;111:1263-9.
- 972 11. Congdon NG, Quigley HA, Hung PT, Wang TH, Ho TC. Screening techniques for angle-closure  
973 glaucoma in rural Taiwan. *Acta Ophthalmol Scand* 1996;74:113-9.
- 974 12. Ong EL, Baasanhu J, Nolan W, Uranchimeg D, Lee PS, Alsbirk PH, Johnson GJ, Foster PJ. The  
975 utility of symptoms in identification of primary angle-closure in a high-risk population. *Ophthalmology*  
976 2008;115:2024-9.
- 977 13. Boodhna T, Crabb DP. Disease severity in newly diagnosed glaucoma patients with visual field loss:  
978 trends from more than a decade of data. *Ophthalmic Physiol Opt* 2015;35:225-30.
- 979 14. Varma DK, Simpson SM, Rai AS, Ahmed IIK. Undetected angle closure in patients with a diagnosis  
980 of open-angle glaucoma. *Can J Ophthalmol* 2017;52:373-8.
- 981 15. Emanuel ME, Parrish RK, 2nd, Gedde SJ. Evidence-based management of primary angle closure  
982 glaucoma. *Curr Opin Ophthalmol* 2014;25:89-92.
- 983 16. Prum BE, Jr., Herndon LW, Jr., Moroi SE, Mansberger SL, Stein JD, Lim MC, Rosenberg LF,  
984 Gedde SJ, Williams RD. Primary Angle Closure Preferred Practice Pattern((R)) Guidelines. *Ophthalmology*  
985 2016;123:P1-P40.
- 986 17. Thomas R, Walland MJ. Management algorithms for primary angle closure disease: response. *Clin*  
987 *Exp Ophthalmol* 2014;42:401-2.
- 988 18. Foster PJ, Buhrmann R, Quigley HA, Johnson GJ. The definition and classification of glaucoma in  
989 prevalence surveys. *Br J Ophthalmol* 2002;86:238-42.
- 990 19. Walland MJ, Thomas R. 'So what's our angle on this?'. *Clin Exp Ophthalmol* 2010;38:743-4.
- 991 20. Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, Azuara-Blanco A,  
992 Bourne RR, Broadway DC, Cunliffe IA, Diamond JP, Fraser SG, Ho TA, Martin KR, McNaught AI, Negi A,  
993 Patel K, Russell RA, Shah A, Spry PG, Suzuki K, White ET, Wormald RP, Xing W, Zeyen TG. Latanoprost  
994 for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. *Lancet*  
995 2015;385:1295-304.
- 996 21. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK, 2nd,  
997 Wilson MR, Gordon MO. The Ocular Hypertension Treatment Study: a randomized trial determines that  
998 topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. *Arch*  
999 *Ophthalmol* 2002;120:701-13; discussion 829-30.

#### *Diplomate case 4: Primary angle closure*

- 1000 22. Miglior S, Zeyen T, Pfeiffer N, Cunha-Vaz J, Torri V, Adamsons I, European Glaucoma Prevention  
1001 Study G. The European glaucoma prevention study design and baseline description of the participants.  
1002 *Ophthalmology* 2002;109:1612-21.
- 1003 23. Musch DC, Lichter PR, Guire KE, Standardi CL. The Collaborative Initial Glaucoma Treatment  
1004 Study: study design, methods, and baseline characteristics of enrolled patients. *Ophthalmology*  
1005 1999;106:653-62.
- 1006 24. Forbes M. Gonioscopy with corneal indentation. A method for distinguishing between appositional  
1007 closure and synechial closure. *Arch Ophthalmol* 1966;76:488-92.
- 1008 25. Asia Pacific Glaucoma Society (APGS). Asia Pacific Glaucoma Guidelines. Amsterdam, The  
1009 Netherlands: Kugler Publications; 2016 [updated 2016. Available at:  
1010 [http://www.icoph.org/dynamic/attachments/resources/asia\\_pacific\\_glaucoma\\_guidelines\\_2016\\_third\\_edition](http://www.icoph.org/dynamic/attachments/resources/asia_pacific_glaucoma_guidelines_2016_third_edition.pdf)  
1011 [.pdf](http://www.icoph.org/dynamic/attachments/resources/asia_pacific_glaucoma_guidelines_2016_third_edition.pdf). Accessed: 9th October 2018];
- 1012 26. International Council of Ophthalmology. International Council of Ophthalmology Guidelines for  
1013 Glaucoma Eye Care. 2016 [updated 2016. Available at:  
1014 <http://www.icoph.org/downloads/ICOGlaucomaGuidelines.pdf>. Accessed: 9th October 2018];
- 1015 27. International Council of Ophthalmology. Primary angle closure (initial evaluation and therapy).  
1016 2010 [updated 2010. Available at:  
1017 [http://www.icoph.org/dynamic/attachments/resources/icopriangleclosure\\_2.pdf](http://www.icoph.org/dynamic/attachments/resources/icopriangleclosure_2.pdf). Accessed: 9th October  
1018 2018];
- 1019 28. Sihota R. Classification of primary angle closure disease. *Curr Opin Ophthalmol* 2011;22:87-95.
- 1020 29. Inoue T. [Distribution and morphology of peripheral anterior synechia in primary angle-closure  
1021 glaucoma]. *Nippon Ganka Gakkai Zasshi* 1993;97:78-82.
- 1022 30. Liu L, Foster PJ. Highs and lows of peripheral anterior synechiae. *Clin Exp Ophthalmol*  
1023 2012;40:211-2.
- 1024 31. Sun JH, Sung KR, Yun SC, Cheon MH, Tchah HW, Kim MJ, Kim JY. Factors associated with  
1025 anterior chamber narrowing with age: an optical coherence tomography study. *Invest Ophthalmol Vis Sci*  
1026 2012;53:2607-10.
- 1027 32. Inomata H, Tawara A. Anterior and posterior parts of human trabecular meshwork. *Jpn J*  
1028 *Ophthalmol* 1984;28:339-48.
- 1029 33. Rouhiainen H, Terasvirta M. Pigmentation of the anterior chamber angle in normal and  
1030 pseudoexfoliative eyes. *Acta Ophthalmol (Copenh)* 1990;68:700-2.
- 1031 34. Carreon T, van der Merwe E, Fellman RL, Johnstone M, Bhattacharya SK. Aqueous outflow - A  
1032 continuum from trabecular meshwork to episcleral veins. *Prog Retin Eye Res* 2017;57:108-33.
- 1033 35. Akil H, Dastiridou A, Marion K, Francis BA, Chopra V. Effects of diurnal, lighting, and angle-of-  
1034 incidence variation on anterior segment optical coherence tomography (AS-OCT) angle metrics. *BMC*  
1035 *Ophthalmol* 2017;17:31.
- 1036 36. Arimura S, Takamura Y, Takihara Y, Matsumura T, Tomomatsu T, Inatani M. Determinants of  
1037 anterior chamber angle narrowing after mydriasis in the patients with cataract. *Graefes Arch Clin Exp*  
1038 *Ophthalmol* 2015;253:307-12.
- 1039 37. Dastiridou AI, Pan X, Zhang Z, Marion KM, Francis BA, Sadda SR, Chopra V. Comparison of  
1040 Physiologic versus Pharmacologic Mydriasis on Anterior Chamber Angle Measurements Using Spectral  
1041 Domain Optical Coherence Tomography. *J Ophthalmol* 2015;2015:845643.
- 1042 38. Liu L. Anatomical changes of the anterior chamber angle with anterior-segment optical coherence  
1043 tomography. *Arch Ophthalmol* 2008;126:1682-6.
- 1044 39. Thomas R, George R, Parikh R, Muliylil J, Jacob A. Five year risk of progression of primary angle  
1045 closure suspects to primary angle closure: a population based study. *Br J Ophthalmol* 2003;87:450-4.
- 1046 40. Thomas R, Parikh R, Muliylil J, Kumar RS. Five-year risk of progression of primary angle closure to  
1047 primary angle closure glaucoma: a population-based study. *Acta Ophthalmol Scand* 2003;81:480-5.
- 1048 41. Yip JL, Foster PJ, Uranchimeg D, Javzandulam B, Javzansuren D, Munhzaya T, Lee PS,  
1049 Baassanhuu J, Gilbert CE, Khaw PT, Johnson GJ, Nolan WP. Randomised controlled trial of screening and  
1050 prophylactic treatment to prevent primary angle closure glaucoma. *Br J Ophthalmol* 2010;94:1472-7.
- 1051 42. Mwanza JC, Budenz DL. Optical coherence tomography platforms and parameters for glaucoma  
1052 diagnosis and progression. *Curr Opin Ophthalmol* 2016;27:102-10.
- 1053 43. Mills RP, Budenz DL, Lee PP, Noecker RJ, Walt JG, Siegartel LR, Evans SJ, Doyle JJ. Categorizing  
1054 the stage of glaucoma from pre-diagnosis to end-stage disease. *Am J Ophthalmol* 2006;141:24-30.

*Diplomate case 4: Primary angle closure*

- 1055 44. Ferris FL, Davis MD, Clemons TE, Lee LY, Chew EY, Lindblad AS, Milton RC, Bressler SB, Klein  
1056 R, Age-Related Eye Disease Study Research G. A simplified severity scale for age-related macular  
1057 degeneration: AREDS Report No. 18. *Arch Ophthalmol* 2005;123:1570-4.
- 1058 45. Pathak M, Demirel S, Gardiner SK. Nonlinear, multilevel mixed-effects approach for modeling  
1059 longitudinal standard automated perimetry data in glaucoma. *Invest Ophthalmol Vis Sci* 2013;54:5505-13.
- 1060 46. Richdale K, Bullimore MA, Sinnott LT, Zadnik K. The Effect of Age, Accommodation, and  
1061 Refractive Error on the Adult Human Eye. *Optom Vis Sci* 2016;93:3-11.
- 1062 47. Pierscionek B, Bahrami M, Hoshino M, Uesugi K, Regini J, Yagi N. The eye lens: age-related trends  
1063 and individual variations in refractive index and shape parameters. *Oncotarget* 2015;6:30532-44.
- 1064 48. Richdale K, Bullimore MA, Zadnik K. Lens thickness with age and accommodation by optical  
1065 coherence tomography. *Ophthalmic Physiol Opt* 2008;28:441-7.
- 1066 49. Fotedar R, Wang JJ, Burlutsky G, Morgan IG, Rose K, Wong TY, Mitchell P. Distribution of axial  
1067 length and ocular biometry measured using partial coherence laser interferometry (IOL Master) in an older  
1068 white population. *Ophthalmology* 2010;117:417-23.
- 1069 50. Hashemi H, Khabazkhoob M, Iribarren R, Emamian MH, Fotouhi A. Five-year change in refraction  
1070 and its ocular components in the 40- to 64-year-old population of the Shahroud eye cohort study. *Clin Exp*  
1071 *Ophthalmol* 2016;44:669-77.
- 1072 51. He Y, Baskaran M, Narayanaswamy AK, Sakata LM, Wu R, Liu D, Nongpiur ME, He M, Friedman  
1073 DS, Aung T. Changes in anterior segment dimensions over 4 years in a cohort of Singaporean subjects with  
1074 open angles. *Br J Ophthalmol* 2015;99:1097-102.
- 1075 52. Yong KL, Gong T, Nongpiur ME, How AC, Lee HK, Cheng L, Perera SA, Aung T. Myopia in asian  
1076 subjects with primary angle closure: implications for glaucoma trends in East Asia. *Ophthalmology*  
1077 2014;121:1566-71.
- 1078 53. Jin G, Ding X, Guo X, Chang BH, Odouard C, He M. Does Myopia Affect Angle Closure  
1079 Prevalence. *Invest Ophthalmol Vis Sci* 2015;56:5714-9.
- 1080 54. Barkana Y, Shihadeh W, Oliveira C, Tello C, Liebmann JM, Ritch R. Angle closure in highly  
1081 myopic eyes. *Ophthalmology* 2006;113:247-54.
- 1082 55. Li M, Chen Y, Jiang Z, Chen X, Chen J, Sun X. What Are the Characteristics of Primary Angle  
1083 Closure With Longer Axial Length? *Invest Ophthalmol Vis Sci* 2018;59:1354-9.
- 1084 56. Kalantzis G, Georgalas I, Tsiamis C, El-Hindy N, Poulakou-Rebelakou E. The invention of  
1085 gonioscopy by Alexios Trantas and his contribution to ophthalmology. *J R Coll Physicians Edinb*  
1086 2015;45:226-8.
- 1087 57. Campbell DG. A comparison of diagnostic techniques in angle-closure glaucoma. *Am J Ophthalmol*  
1088 1979;88:197-204.
- 1089 58. Spaeth GL. The normal development of the human anterior chamber angle: a new system of  
1090 descriptive grading. *Trans Ophthalmol Soc U K* 1971;91:709-39.
- 1091 59. Dastiridou A, Marion K, Niemeyer M, Francis B, Sadda S, Chopra V. Pilot Study of the Effects of  
1092 Ambient Light Level Variation on Spectral Domain Anterior Segment OCT-Derived Angle Metrics in  
1093 Caucasians versus Asians. *Curr Eye Res* 2018;43:955-9.
- 1094 60. Friedman DS, Gazzard G, Foster P, Devereux J, Broman A, Quigley H, Tielsch J, Seah S.  
1095 Ultrasonographic biomicroscopy, Scheimpflug photography, and novel provocative tests in contralateral eyes  
1096 of Chinese patients initially seen with acute angle closure. *Arch Ophthalmol* 2003;121:633-42.
- 1097 61. Barkana Y, Dorairaj SK, Gerber Y, Liebmann JM, Ritch R. Agreement between gonioscopy and  
1098 ultrasound biomicroscopy in detecting iridotrabecular apposition. *Arch Ophthalmol* 2007;125:1331-5.
- 1099 62. Wilensky JT, Ritch R, Kolker AE. Should patients with anatomically narrow angles have  
1100 prophylactic iridectomy? *Surv Ophthalmol* 1996;41:31-6.
- 1101 63. Li D, Wang N, Wang B, Wang T, Jonas JB. Modified dark room provocative test for primary angle  
1102 closure. *J Glaucoma* 2012;21:155-9.
- 1103 64. Smith SD, Singh K, Lin SC, Chen PP, Chen TC, Francis BA, Jampel HD. Evaluation of the anterior  
1104 chamber angle in glaucoma: a report by the american academy of ophthalmology. *Ophthalmology*  
1105 2013;120:1985-97.
- 1106 65. Shaffer RN. Stereoscopic manual of gonioscopy. St Louis: Mosby; 1962.
- 1107 66. Scheie HG. Width and pigmentation of the angle of the anterior chamber; a system of grading by  
1108 gonioscopy. *AMA Arch Ophthalmol* 1957;58:510-2.

*Diplomate case 4: Primary angle closure*

- 1109 67. Choudhari NS, Pathak-Ray V, Kaushik S, Vyas P, George R. Understanding practice patterns of  
1110 glaucoma sub-specialists in India. *Int J Ophthalmol* 2017;10:1580-5.
- 1111 68. Zebardast N, Solus JF, Quigley HA, Srikumaran D, Ramulu PY. Comparison of resident and  
1112 glaucoma faculty practice patterns in the care of open-angle glaucoma. *BMC Ophthalmol* 2015;15:41.
- 1113 69. Elam AR, Blachley TS, Stein JD. Geographic Variation in the Use of Diagnostic Testing of Patients  
1114 with Newly Diagnosed Open-Angle Glaucoma. *Ophthalmology* 2016;123:522-31.
- 1115 70. Liu L. Australia and New Zealand survey of glaucoma practice patterns. *Clin Exp Ophthalmol*  
1116 2008;36:19-25.
- 1117 71. Hertzog LH, Albrecht KG, LaBree L, Lee PP. Glaucoma care and conformance with preferred  
1118 practice patterns. Examination of the private, community-based ophthalmologist. *Ophthalmology*  
1119 1996;103:1009-13.
- 1120 72. Jamous KF, Kalloniatis M, Hayen A, Mitchell P, Stapleton FJ, Zangerl B. Application of clinical  
1121 techniques relevant for glaucoma assessment by optometrists: concordance with guidelines. *Ophthalmic*  
1122 *Physiol Opt* 2014;34:580-91.
- 1123 73. Gaskin BJ, Carroll SC, Gamble G, Goldberg I, Danesh-Meyer HV. Glaucoma management trends in  
1124 Australia and New Zealand. *Clin Exp Ophthalmol* 2006;34:208-12.
- 1125 74. Ang MH, Baskaran M, Kumar RS, Chew PT, Oen FT, Wong HT, Jap A, Au Eong KG, Seah SK,  
1126 Aung T. National survey of ophthalmologists in Singapore for the assessment and management of  
1127 asymptomatic angle closure. *J Glaucoma* 2008;17:1-4.
- 1128 75. Zangerl B, Hayen A, Mitchell P, Jamous KF, Stapleton F, Kalloniatis M. Therapeutic endorsement  
1129 enhances compliance with national glaucoma guidelines in Australian and New Zealand optometrists.  
1130 *Ophthalmic Physiol Opt* 2015;35:212-24.
- 1131 76. Van Herick W, Shaffer RN, Schwartz A. Estimation of width of angle of anterior chamber.  
1132 Incidence and significance of the narrow angle. *Am J Ophthalmol* 1969;68:626-9.
- 1133 77. Foster PJ, Devereux JG, Alsbirk PH, Lee PS, Uranchimeg D, Machin D, Johnson GJ, Baasanhu J.  
1134 Detection of gonioscopically occludable angles and primary angle closure glaucoma by estimation of limbal  
1135 chamber depth in Asians: modified grading scheme. *Br J Ophthalmol* 2000;84:186-92.
- 1136 78. Cockburn DM. A new method for gonioscopic grading of the anterior chamber angle. *Am J Optom*  
1137 *Physiol Opt* 1980;57:258-61.
- 1138 79. Thomas R, George T, Braganza A, Muliyl J. The flashlight test and van Herick's test are poor  
1139 predictors for occludable angles. *Aust N Z J Ophthalmol* 1996;24:251-6.
- 1140 80. Javed A, Loutfi M, Kaye S, Batterbury M. Interobserver reliability when using the Van Herick  
1141 method to measure anterior chamber depth. *Oman J Ophthalmol* 2017;10:9-12.
- 1142 81. Jindal A, Myint J, Edgar DF, Nolan WP, Lawrenson JG. Agreement among optometrists and  
1143 ophthalmologists in estimating limbal anterior chamber depth using the van Herick method. *Ophthalmic*  
1144 *Physiol Opt* 2015;35:179-85.
- 1145 82. Smith RJ. A new method of estimating the depth of the anterior chamber. *Br J Ophthalmol*  
1146 1979;63:215-20.
- 1147 83. Dabasia PL, Edgar DF, Murdoch IE, Lawrenson JG. Noncontact Screening Methods for the  
1148 Detection of Narrow Anterior Chamber Angles. *Invest Ophthalmol Vis Sci* 2015;56:3929-35.
- 1149 84. Hockwin O, Weigelin E, Laser H, Dragomirescu V. Biometry of the anterior eye segment by  
1150 Scheimpflug photography. *Ophthalmic Res* 1983;15:102-8.
- 1151 85. Rossi GC, Scudeller L, Delfino A, Raimondi M, Pezzotta S, Maccarone M, Antoniazzi E, Pasinetti  
1152 GM, Bianchi PE. Pentacam sensitivity and specificity in detecting occludable angles. *Eur J Ophthalmol*  
1153 2012;22:701-8.
- 1154 86. Grewal DS, Brar GS, Jain R, Grewal SP. Comparison of Scheimpflug imaging and spectral domain  
1155 anterior segment optical coherence tomography for detection of narrow anterior chamber angles. *Eye (Lond)*  
1156 2011;25:603-11.
- 1157 87. Kurita N, Mayama C, Tomidokoro A, Aihara M, Araie M. Potential of the pentacam in screening for  
1158 primary angle closure and primary angle closure suspect. *J Glaucoma* 2009;18:506-12.
- 1159 88. Pakravan M, Sharifipour F, Yazdani S, Koohestani N, Yaseri M. Scheimpflug imaging criteria for  
1160 identifying eyes at high risk of acute angle closure. *J Ophthalmic Vis Res* 2012;7:111-7.
- 1161 89. Winegarner A, Miki A, Kumoi M, Ishida Y, Wakabayashi T, Sakimoto S, Usui S, Matsushita K,  
1162 Nishida K. Anterior segment Scheimpflug imaging for detecting primary angle closure disease. *Graefes Arch*  
1163 *Clin Exp Ophthalmol* 2018.

*Diplomate case 4: Primary angle closure*

- 1164 90. Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, Hee MR, Flotte T, Gregory K,  
1165 Puliafito CA, et al. Optical coherence tomography. *Science* 1991;254:1178-81.
- 1166 91. Izatt JA, Hee MR, Swanson EA, Lin CP, Huang D, Schuman JS, Puliafito CA, Fujimoto JG.  
1167 Micrometer-scale resolution imaging of the anterior eye in vivo with optical coherence tomography. *Arch*  
1168 *Ophthalmol* 1994;112:1584-9.
- 1169 92. Radhakrishnan S, Rollins AM, Roth JE, Yazdanfar S, Westphal V, Bardenstein DS, Izatt JA. Real-  
1170 time optical coherence tomography of the anterior segment at 1310 nm. *Arch Ophthalmol* 2001;119:1179-  
1171 85.
- 1172 93. Ang M, Baskaran M, Werkmeister RM, Chua J, Schmidl D, Aranha Dos Santos V, Garhofer G,  
1173 Mehta JS, Schmetterer L. Anterior segment optical coherence tomography. *Prog Retin Eye Res* 2018;66:132-  
1174 56.
- 1175 94. McKee H, Ye C, Yu M, Liu S, Lam DS, Leung CK. Anterior chamber angle imaging with swept-  
1176 source optical coherence tomography: detecting the scleral spur, Schwalbe's Line, and Schlemm's Canal. *J*  
1177 *Glaucoma* 2013;22:468-72.
- 1178 95. Sakata LM, Lavanya R, Friedman DS, Aung HT, Gao H, Kumar RS, Foster PJ, Aung T. Comparison  
1179 of gonioscopy and anterior segment ocular coherence tomography in detecting angle closure in different  
1180 quadrants of the anterior chamber angle. *Ophthalmology* 2008;115:769-74.
- 1181 96. Narayanaswamy A, Sakata LM, He MG, Friedman DS, Chan YH, Lavanya R, Baskaran M, Foster  
1182 PJ, Aung T. Diagnostic performance of anterior chamber angle measurements for detecting eyes with narrow  
1183 angles: an anterior segment OCT study. *Arch Ophthalmol* 2010;128:1321-7.
- 1184 97. Nongpiur ME, Sakata LM, Friedman DS, He M, Chan YH, Lavanya R, Wong TY, Aung T. Novel  
1185 association of smaller anterior chamber width with angle closure in Singaporeans. *Ophthalmology*  
1186 2010;117:1967-73.
- 1187 98. Tan GS, He M, Zhao W, Sakata LM, Li J, Nongpiur ME, Lavanya R, Friedman DS, Aung T.  
1188 Determinants of lens vault and association with narrow angles in patients from Singapore. *Am J Ophthalmol*  
1189 2012;154:39-46.
- 1190 99. Wang B, Sakata LM, Friedman DS, Chan YH, He M, Lavanya R, Wong TY, Aung T. Quantitative  
1191 iris parameters and association with narrow angles. *Ophthalmology* 2010;117:11-7.
- 1192 100. Samaha D, Gagne S, Corbeil M-E, Porcier P. Predicting primary angle closure suspects using  
1193 anterior segment OCT: A new approach. In: American Academy of Optometry Annual Meeting. San  
1194 Antonio, TX; 2018.
- 1195 101. Pavlin CJ, Harasiewicz K, Foster FS. Ultrasound biomicroscopy of anterior segment structures in  
1196 normal and glaucomatous eyes. *Am J Ophthalmol* 1992;113:381-9.
- 1197 102. He M, Foster PJ, Ge J, Huang W, Wang D, Friedman DS, Khaw PT. Gonioscopy in adult Chinese:  
1198 the Liwan Eye Study. *Invest Ophthalmol Vis Sci* 2006;47:4772-9.
- 1199 103. Rosenblum H, Radcliffe N. Case-based approach to managing angle closure glaucoma with anterior  
1200 segment imaging. *Can J Ophthalmol* 2014;49:512-8.
- 1201 104. Lowe RF. Angle-closure, pupil dilatation, and pupil block. *Br J Ophthalmol* 1966;50:385-9.
- 1202 105. Ritch R. Plateau iris is caused by abnormally positioned ciliary processes. *J Glaucoma* 1992;1:23-6.
- 1203 106. Wand M, Grant WM, Simmons RJ, Hutchinson BT. Plateau iris syndrome. *Trans Sect Ophthalmol*  
1204 *Am Acad Ophthalmol Otolaryngol* 1977;83:122-30.
- 1205 107. Kumar RS, Baskaran M, Chew PT, Friedman DS, Handa S, Lavanya R, Sakata LM, Wong HT,  
1206 Aung T. Prevalence of plateau iris in primary angle closure suspects an ultrasound biomicroscopy study.  
1207 *Ophthalmology* 2008;115:430-4.
- 1208 108. Moghimi S, Ramezani F, He M, Coleman AL, Lin SC. Comparison of Anterior Segment-Optical  
1209 Coherence Tomography Parameters in Phacomorphic Angle Closure and Acute Angle Closure Eyes. *Invest*  
1210 *Ophthalmol Vis Sci* 2015;56:7611-7.
- 1211 109. Nongpiur ME, Singhal S, Stewart S, Htoon HM, Narayanaswamy AK, Wong TY, Perera SA, Aung  
1212 T. The Impact of Lens Vault on Visual Acuity and Refractive Error: Implications for Management of  
1213 Primary Angle-closure Glaucoma. *J Glaucoma* 2016;25:e236-40.
- 1214 110. Kim YK, Yoo BW, Kim HC, Aung T, Park KH. Relative lens vault in subjects with angle closure.  
1215 *BMC Ophthalmol* 2014;14:93.
- 1216 111. Trikha S, Perera SA, Husain R, Aung T. The role of lens extraction in the current management of  
1217 primary angle-closure glaucoma. *Curr Opin Ophthalmol* 2015;26:128-34.

#### *Diplomate case 4: Primary angle closure*

- 1218 112. Lee RY, Huang G, Cui QN, He M, Porco TC, Lin SC. Association of lens vault with narrow angles  
1219 among different ethnic groups. *Curr Eye Res* 2012;37:486-91.
- 1220 113. Cashwell LF, Martin TJ. Malignant glaucoma after laser iridotomy. *Ophthalmology* 1992;99:651-8;  
1221 discussion 8-9.
- 1222 114. Hanish SJ, Lamberg RL, Gordon JM. Malignant glaucoma following cataract extraction and  
1223 intraocular lens implant. *Ophthalmic Surg* 1982;13:713-4.
- 1224 115. Ruben S, Tsai J, Hitchings RA. Malignant glaucoma and its management. *Br J Ophthalmol*  
1225 1997;81:163-7.
- 1226 116. Wilensky JT, Kaufman PL, Frohlichstein D, Gieser DK, Kass MA, Ritch R, Anderson R. Follow-up  
1227 of angle-closure glaucoma suspects. *Am J Ophthalmol* 1993;115:338-46.
- 1228 117. Yip JL, Foster PJ, Gilbert CE, Uranchimeg D, Bassanhuu J, Lee PS, Khaw PT, Johnson GJ, Nolan  
1229 W. Incidence of occludable angles in a high-risk Mongolian population. *Br J Ophthalmol* 2008;92:30-3.
- 1230 118. Ko YC, Liu CJ, Hsu WM, Cheng CY, Kuang TM, Chou P. Determinants and characteristics of  
1231 angle-closure disease in an elderly Chinese population. *Ophthalmic Epidemiol* 2015;22:109-15.
- 1232 119. Zhang X, Liu Y, Wang W, Chen S, Li F, Huang W, Aung T, Wang N. Why does acute primary  
1233 angle closure happen? Potential risk factors for acute primary angle closure. *Surv Ophthalmol* 2017;62:635-  
1234 47.
- 1235 120. Salmon JF. Predisposing factors for chronic angle-closure glaucoma. *Prog Retin Eye Res*  
1236 1999;18:121-32.
- 1237 121. Marchini G, Chemello F, Berzaghi D, Zampieri A. New findings in the diagnosis and treatment of  
1238 primary angle-closure glaucoma. *Prog Brain Res* 2015;221:191-212.
- 1239 122. Shen L, Melles RB, Metlapally R, Barcellos L, Schaefer C, Risch N, Herrinton LJ, Wildsoet C,  
1240 Jorgenson E. The Association of Refractive Error with Glaucoma in a Multiethnic Population.  
1241 *Ophthalmology* 2016;123:92-101.
- 1242 123. Sawaguchi S, Sakai H, Iwase A, Yamamoto T, Abe H, Tomita G, Tomidokoro A, Araie M.  
1243 Prevalence of primary angle closure and primary angle-closure glaucoma in a southwestern rural population  
1244 of Japan: the Kumejima Study. *Ophthalmology* 2012;119:1134-42.
- 1245 124. Mohamed-Noor J, Abd-Salam D. Refractive errors and biometry of primary angle-closure disease in  
1246 a mixed Malaysian population. *Int J Ophthalmol* 2017;10:1246-50.
- 1247 125. Senthil S, Garudadri C, Khanna RC, Sannapaneni K. Angle closure in the Andhra Pradesh Eye  
1248 Disease Study. *Ophthalmology* 2010;117:1729-35.
- 1249 126. Van Rens GH, Arkell SM, Charlton W, Doesburg W. Primary angle-closure glaucoma among  
1250 Alaskan Eskimos. *Doc Ophthalmol* 1988;70:265-76.
- 1251 127. Arkell SM, Lightman DA, Sommer A, Taylor HR, Korshin OM, Tielsch JM. The prevalence of  
1252 glaucoma among Eskimos of northwest Alaska. *Arch Ophthalmol* 1987;105:482-5.
- 1253 128. Casson RJ. Anterior chamber depth and primary angle-closure glaucoma: an evolutionary  
1254 perspective. *Clin Exp Ophthalmol* 2008;36:70-7.
- 1255 129. Robin AL, Pollack IP, Quigley HA, D'Anna S, Addicks EM. Histologic studies of angle structures  
1256 after laser iridotomy in primates. *Arch Ophthalmol* 1982;100:1665-70.
- 1257 130. Vera V, Naqi A, Belovay GW, Varma DK, Ahmed, II. Dysphotopsia after temporal versus superior  
1258 laser peripheral iridotomy: a prospective randomized paired eye trial. *Am J Ophthalmol* 2014;157:929-35.
- 1259 131. Woo WW, Wride NK, Fraser SG. Dysphotopsia after temporal versus superior laser peripheral  
1260 iridotomy: a prospective randomized paired eye trial. *Am J Ophthalmol* 2014;158:849-50.
- 1261 132. Belovay GW, Vera V, Varma DK, Ahmed IIK. Re: Srinivasan et al.: Comparison of new visual  
1262 disturbances after superior versus nasal/temporal laser peripheral iridotomy: a prospective randomized trial  
1263 (*Ophthalmology*. 2018;125:345-351). *Ophthalmology* 2018;125:e36.
- 1264 133. Srinivasan K, Zebardast N, Krishnamurthy P, Abdul Kader M, Raman GV, Rajendrababu S,  
1265 Venkatesh R, Ramulu PY. Comparison of New Visual Disturbances after Superior versus Nasal/Temporal  
1266 Laser Peripheral Iridotomy: A Prospective Randomized Trial. *Ophthalmology* 2018;125:345-51.
- 1267 134. Ahmadi M, Naderi Beni Z, Naderi Beni A, Kianersi F. Efficacy of neodymium-doped yttrium  
1268 aluminum garnet laser iridotomies in primary angle-closure diseases: superior peripheral iridotomy versus  
1269 inferior peripheral iridotomy. *Curr Med Res Opin* 2017;33:687-92.
- 1270 135. de Silva DJ, Day AC, Bunce C, Gazzard G, Foster PJ. Randomised trial of sequential pretreatment  
1271 for Nd:YAG laser iridotomy in dark irides. *Br J Ophthalmol* 2012;96:263-6.
- 1272 136. de Silva DJ, Gazzard G, Foster P. Laser iridotomy in dark irides. *Br J Ophthalmol* 2007;91:222-5.

*Diplomate case 4: Primary angle closure*

- 1273 137. Lim L, Seah SK, Lim AS. Comparison of argon laser iridotomy and sequential argon laser and  
1274 Nd:YAG laser iridotomy in dark irides. *Ophthalmic Surg Lasers* 1996;27:285-8.
- 1275 138. Ho T, Fan R. Sequential argon-YAG laser iridotomies in dark irides. *Br J Ophthalmol* 1992;76:329-  
1276 31.
- 1277 139. Bochmann F, Johnson Z, Atta HR, Azuara-Blanco A. Increasing the size of a small peripheral  
1278 iridotomy widens the anterior chamber angle: an ultrasound biomicroscopy study. *Klin Monbl Augenheilkd*  
1279 2008;225:349-52.
- 1280 140. Fleck BW. How large must an iridotomy be? *Br J Ophthalmol* 1990;74:583-8.
- 1281 141. Krupin T, Stone RA, Cohen BH, Kolker AE, Kass MA. Acute intraocular pressure response to argon  
1282 laser iridotomy. *Ophthalmology* 1985;92:922-6.
- 1283 142. Lewis R, Perkins TW, Gangnon R, Kaufman PL, Heatley GA. The rarity of clinically significant rise  
1284 in intraocular pressure after laser peripheral iridotomy with apraclonidine. *Ophthalmology* 1998;105:2256-9.
- 1285 143. Siam GA, de Barros DS, Gheith ME, Batiste CG, Tittler EH, Moster MR, Spaeth GL. Post-  
1286 peripheral iridotomy inflammation in patients with dark pigmentation. *Ophthalmic Surg Lasers Imaging*  
1287 2008;39:49-53.
- 1288 144. Ali A, Rosenfeld C, Rosenberg E, Sharma S, Wandel TL. Chronic Uveitis Following Neodymium-  
1289 Doped Yttrium Aluminum Garnet Laser Peripheral Iridotomy. *J Glaucoma* 2017;26:e229-e31.
- 1290 145. Golan S, Levkovitch-Verbin H, Shemesh G, Kurtz S. Anterior chamber bleeding after laser  
1291 peripheral iridotomy. *JAMA Ophthalmol* 2013;131:626-9.
- 1292 146. Seong M, Kim MJ, Tchah H. Argon laser iridotomy as a possible cause of anterior dislocation of a  
1293 crystalline lens. *J Cataract Refract Surg* 2009;35:190-2.
- 1294 147. Wollensak G, Eberwein P, Funk J. Perforation rosette of the lens after Nd:YAG laser iridotomy. *Am J*  
1295 *Ophthalmol* 1997;123:555-7.
- 1296 148. Wang PX, Koh VT, Loon SC. Laser iridotomy and the corneal endothelium: a systemic review. *Acta*  
1297 *Ophthalmol* 2014;92:604-16.
- 1298 149. Radhakrishnan S, Chen PP, Junk AK, Nouri-Mahdavi K, Chen TC. Laser Peripheral Iridotomy in  
1299 Primary Angle Closure: A Report by the American Academy of Ophthalmology. *Ophthalmology*  
1300 2018;125:1110-20.
- 1301 150. Spaeth GL, Idowu O, Seligsohn A, Henderer J, Fonatanarosa J, Modi A, Nallamshetty HS, Chieh J,  
1302 Haim L, Steinmann WC, Moster M. The effects of iridotomy size and position on symptoms following laser  
1303 peripheral iridotomy. *J Glaucoma* 2005;14:364-7.
- 1304 151. Congdon N, Yan X, Friedman DS, Foster PJ, van den Berg TJ, Peng M, Gangwani R, He M. Visual  
1305 symptoms and retinal straylight after laser peripheral iridotomy: the Zhongshan Angle-Closure Prevention  
1306 Trial. *Ophthalmology* 2012;119:1375-82.
- 1307 152. Schwenn O, Sell F, Pfeiffer N, Grehn F. Prophylactic Nd:YAG-laser iridotomy versus surgical  
1308 iridectomy: a randomized, prospective study. *Ger J Ophthalmol* 1995;4:374-9.
- 1309 153. Ng WS, Ang GS, Azuara-Blanco A. Laser peripheral iridoplasty for angle-closure. *Cochrane*  
1310 *Database Syst Rev* 2012:CD006746.
- 1311 154. Ritch R, Tham CC, Lam DS. Argon laser peripheral iridoplasty (ALPI): an update. *Surv Ophthalmol*  
1312 2007;52:279-88.
- 1313 155. Sun X, Liang YB, Wang NL, Fan SJ, Sun LP, Li SZ, Liu WR. Laser peripheral iridotomy with and  
1314 without iridoplasty for primary angle-closure glaucoma: 1-year results of a randomized pilot study. *Am J*  
1315 *Ophthalmol* 2010;150:68-73.
- 1316 156. Ritch R, Tham CC, Lam DS. Long-term success of argon laser peripheral iridoplasty in the  
1317 management of plateau iris syndrome. *Ophthalmology* 2004;111:104-8.
- 1318 157. Cho HK, Kee C, Yang H, Huh HD, Kim SJ, Park YM, Park JM. Comparison of circumferential  
1319 peripheral angle closure using iridotrabecular contact index after laser iridotomy versus combined laser  
1320 iridotomy and iridoplasty. *Acta Ophthalmol* 2017;95:e539-e47.
- 1321 158. Ramakrishnan R, Mitra A, Abdul Kader M, Das S. To Study the Efficacy of Laser Peripheral  
1322 Iridoplasty in the Treatment of Eyes With Primary Angle Closure and Plateau Iris Syndrome, Unresponsive  
1323 to Laser Peripheral Iridotomy, Using Anterior-Segment OCT as a Tool. *J Glaucoma* 2016;25:440-6.
- 1324 159. Lee JR, Choi JY, Kim YD, Choi J. Laser peripheral iridotomy with iridoplasty in primary angle  
1325 closure suspect: anterior chamber analysis by pentacam. *Korean J Ophthalmol* 2011;25:252-6.

*Diplomate case 4: Primary angle closure*

- 1326 160. Peterson JR, Anderson JW, Blieden LS, Chuang AZ, Feldman RM, Bell NP. Long-term Outcome of  
1327 Argon Laser Peripheral Iridoplasty in the Management of Plateau Iris Syndrome Eyes. *J Glaucoma*  
1328 2017;26:780-6.
- 1329 161. Pillunat KR, Spoerl E, Orphal J, Pillunat LE. Argon laser peripheral iridoplasty for chronic primary  
1330 angle-closure and angle-closure glaucoma in caucasians. *Acta Ophthalmol* 2018.
- 1331 162. Lim DK, Chan HW, Zheng C, Aquino MC, Wong WL, Ritch R, Chew PT. Quantitative assessment  
1332 of changes in anterior segment morphology after argon laser peripheral iridoplasty: findings from the EARL  
1333 study group. *Clin Exp Ophthalmol* 2018.
- 1334 163. Narayanaswamy A, Baskaran M, Perera SA, Nongpiur ME, Htoon HM, Tun TA, Wong TT, Goh D,  
1335 Su DH, Chew PT, Ho CL, Aung T. Argon Laser Peripheral Iridoplasty for Primary Angle-Closure  
1336 Glaucoma: A Randomized Controlled Trial. *Ophthalmology* 2016;123:514-21.
- 1337 164. Dada T, Rathi A, Angmo D, Agarwal T, Vanathi M, Khokhar SK, Vajpayee RB. Clinical outcomes  
1338 of clear lens extraction in eyes with primary angle closure. *J Cataract Refract Surg* 2015;41:1470-7.
- 1339 165. Melese E, Peterson JR, Feldman RM, Baker LA, Bell NP, Chuang AZ, Blieden LS. Comparing  
1340 Laser Peripheral Iridotomy to Cataract Extraction in Narrow Angle Eyes Using Anterior Segment Optical  
1341 Coherence Tomography. *PLoS One* 2016;11:e0162283.
- 1342 166. Day AC, Cooper D, Burr J, Foster PJ, Friedman DS, Gazzard G, Che-Hamzah J, Aung T, Ramsay  
1343 CR, Azuara-Blanco A. Clear lens extraction for the management of primary angle closure glaucoma: surgical  
1344 technique and refractive outcomes in the EAGLE cohort. *Br J Ophthalmol* 2018.
- 1345 167. Chan W, Garcia JA, Newland HS, Muecke J, McGovern S, Selva D, Aung T, Casson RJ. Killing  
1346 two birds with one stone: the potential effect of cataract surgery on the incidence of primary angle-closure  
1347 glaucoma in a high-risk population. *Clin Exp Ophthalmol* 2012;40:e128-34.
- 1348 168. Azuara-Blanco A, Burr J, Ramsay C, Cooper D, Foster PJ, Friedman DS, Scotland G, Javanbakht M,  
1349 Cochran C, Norrie J, group Es. Effectiveness of early lens extraction for the treatment of primary angle-  
1350 closure glaucoma (EAGLE): a randomised controlled trial. *Lancet* 2016;388:1389-97.
- 1351 169. Jiang Y, Friedman DS, He M, Huang S, Kong X, Foster PJ. Design and methodology of a  
1352 randomized controlled trial of laser iridotomy for the prevention of angle closure in southern China: the  
1353 Zhongshan angle Closure Prevention trial. *Ophthalmic Epidemiol* 2010;17:321-32.
- 1354 170. Jiang Y, Chang DS, Zhu H, Khawaja AP, Aung T, Huang S, Chen Q, Munoz B, Grossi CM, He M,  
1355 Friedman DS, Foster PJ. Longitudinal changes of angle configuration in primary angle-closure suspects: the  
1356 Zhongshan Angle-Closure Prevention Trial. *Ophthalmology* 2014;121:1699-705.
- 1357 171. Azuara-Blanco A, Burr JM, Cochran C, Ramsay C, Vale L, Foster P, Friedman D, Quayyum Z, Lai  
1358 J, Nolan W, Aung T, Chew P, McPherson G, McDonald A, Norrie J. Effectiveness in Angle-closure  
1359 Glaucoma of Lens Extraction Study G. The effectiveness of early lens extraction with intraocular lens  
1360 implantation for the treatment of primary angle-closure glaucoma (EAGLE): study protocol for a  
1361 randomized controlled trial. *Trials* 2011;12:133.
- 1362 172. Javanbakht M, Azuara-Blanco A, Burr JM, Ramsay C, Cooper D, Cochran C, Norrie J, Scotland G.  
1363 Early lens extraction with intraocular lens implantation for the treatment of primary angle closure glaucoma:  
1364 an economic evaluation based on data from the EAGLE trial. *BMJ Open* 2017;7:e013254.
- 1365